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Vitamin D inadequacy is highly prevalent among pregnant women worldwide.
Inadequacy or deficiency of vitamin D can lead to adverse outcomes during pregnancy
such as pre-eclampsia, gestational diabetes, and caesarian section. A systematic review
and meta-analysis were conducted to examine the effectiveness of vitamin D
supplementation on serum vitamin D status during pregnancy in randomized controlled
trials (RCTs). A search was conducted in PubMed, Scopus, ProQuest, EBSCO, Cochrane
CENTRAL Database of Controlled Clinical Trials, PsycINFO, CINAHL, and Google
Scholar, in addition to searching reference lists in published reviews. A comprehensive
list of RCTs of vitamin D status and supplemental use in pregnancy was compiled. The
random effects model was used to determine a summary effect size using pre/post means
and standard deviations of serum vitamin D levels from intervention and control groups.
Sixteen RCTs indicated a large effect size (d = .849, 95% CI .607 – 1.001, p < .001).
Serum vitamin D concentration at delivery was higher with vitamin D supplementation,
and thereby the metabolic outlook was favorable for the mother and newborn.
Heterogeneity of the meta-analysis was significant (Q = 344.418, p < .001); the I-squared

statistic showed moderate heterogeneity (61.89%), which warranted subgroup analysis to
identify possible sources of variation among the studies. Moderators for subgroup
analysis included vitamin D dosages, use of a placebo, use of multivitamins in addition to
vitamin D, duration of interventions, age, low or adequate baseline vitamin D status,
trimester when supplementation was started, country where the RCT was conducted
(USA/UK/AUS versus other countries), and blinded versus non-blinded RCTs. Subgroup
analysis only demonstrated a significant impact on heterogeneity from the trimester
moderator (p < .001). Women who began vitamin D supplementation during the first
trimester had a higher effect size and improved vitamin D status compared to those who
began supplementation in the second or third trimester. Since pregnant women with
vitamin D inadequacy or deficiency are more susceptible to complications, routine
examination of vitamin D status should be conducted in pregnant women.
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CHAPTER I
INTRODUCTION
The required intake of vitamin D has long been discussed as a topic of nutritional
importance to keep the body healthy. As a fat soluble vitamin that is required throughout
the life cycle, it is important for the development, growth, and maintenance of a healthy
body. Vitamin D plays an important role in maintaining calcium and phosphorus levels
(National Institutes of Health [NIH] Office of Dietary Supplements, 2016). The role of
vitamin D during pregnancy is unclear in the outcomes for the mother and fetus. Vitamin
D inadequacy may impact multiple maternal, fetal, and postnatal outcomes (Perez-Lopez,
2012). Optimal health during pregnancy is important to the health of mother and fetus.
Fetal vitamin D status is dependent on maternal status to ensure appropriate maternal
response to calcium demands and neonatal handling of calcium. The levels of 25hydroxyvitamin D (25(OH)D) are usually higher in pregnant women for the purpose of
optimizing calcium homeostasis and appropriate fetal growth and development (PerezLopez, 2012).
The status of vitamin D levels during pregnancy is a measure of serum 25(OH)D
which reflects the total vitamin D intake from food, exposure to sunlight, and
supplements (NIH Office of Dietary Supplements, 2016). Determinants such as dietary
intake, body weight, skin pigmentation, or limited exposure to sunlight impact the rate of
serum 25(OH)D measured in the body. Typically, the status of 25(OH)D is worse in
1

winter months, November through March, and at latitudes above 37°. This limits
exposure of vitamin D to the fetus which may result in complications.
The state of vitamin D metabolism during pregnancy can be quite different and
affect the offspring. During pregnancy, vitamin D metabolism adapts to the physiological
condition of pregnancy. Vitamin D is transported via the placenta to the fetus. Placental
vitamin D receptors and activation enzyme l α-hydroxylase, which is dependent on
cytochrome P-450 (CYP27B1), contribute to adjustments of vitamin D during pregnancy
(Pérez-López, 2012). The metabolism of vitamin D facilitates the transfer of calcium to
the fetus. There is an elevated serum concentration of 1,25-dihydroxyvitamin D
(1,25(OH)2D) to increase calcium absorption in the decidua of the placenta during
pregnancy. This elevated level may offset the physiologic mechanism of calcium loss to
the fetus (Aly, El Koumi, & Abd El Rahman, 2013; Salle, Delvin, Lapillonne, Bishop, &
Glorieux, 2000). The majority of this transfer takes place in the third trimester with the
fetus requiring about 30 grams of calcium during development (Barrett & McElduff,
2010). When serum calcium concentrations decline, circulating levels of 1,25(OH)2D
increase.
Vitamin D inadequacy is highly prevalent among the pregnant population
worldwide (Palacios & Gonzalez, 2014). Vitamin D deficiency among pregnant women
is frequently associated with increased risk of preeclampsia, gestational diabetes mellitus,
and delivery by caesarean section (Kaushal & Magon, 2013; Shin, Choi, Longtine, &
Nelson, 2010). This increases the risk for complications during pregnancy and health
issues of the unborn (Dawodu & Wagner, 2012). The offspring encounter conditions that
are related to low vitamin D status in the mother. Newborns are faced with low birth
2

weight, neonatal rickets, a risk of neonatal hypocalcemia, asthma and/or type 1 diabetes
(Kaushal & Magon, 2013). Both the mother and fetus are at risk when vitamin D
inadequacy or deficiency occurs.
Most women do not obtain the recommended amount of vitamin D from their
diet, sunlight or prenatal vitamins during pregnancy. Prenatal vitamins usually contain
400 IU of vitamin D; however, recommendations are higher to avoid deficiency. The
Institute of Medicine (IOM) guidelines for the Dietary Reference Intake (DRI) of vitamin
D is 600 IU and the tolerable upper limit of intake is 4,000 IU during pregnancy (Ross et
al., 2011). The vitamin D dosage that women should consume during pregnancy to avoid
deficiency is unclear. Serum 25(OH)D testing for high risk individuals during pregnancy
as a preventative measure will signal the need to increase supplementation of vitamin D
in preventing vitamin D deficiency and possible adverse events in pregnancy.
The purpose of the present study was to conduct a systematic review and metaanalysis to determine whether a higher maternal intake of vitamin D during pregnancy
would benefit the mother and fetus. A systematic review and meta-analysis may provide
evidence that vitamin D deficiency can affect maternal status. Randomized controlled
trials (RCTs) are preferred to verify data suggesting that adequate maternal vitamin D
status in pregnancy is necessary for optimal health of mother and fetus. There is a need to
recognize the effects of vitamin D deficiency on health, and screening for vitamin D
status during pregnancy should be conducted to improve the health of mothers and their
infants.
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CHAPTER II
LITERATURE REVIEW
Vitamin D is one of the oldest hormones, made in the earliest life forms of
phytoplankton, zooplankton, and most plants and animals exposed to sunlight (Holick,
2003). The intake of phytoplankton and zooplankton by various oily type fish has given
fish the vitamin D content useful in the human diet (Holick, 2003). Bouillon (2001)
reported that a diet high in oily fish can prevent a vitamin D deficiency.
The discovery of special factors in the diet has been occurring for centuries. In the
early part of the twentieth century, the causes of beriberi, rickets, and other diseases were
reported. The problems created by these diseases led to discovering missing factors in the
diet. Rickets was described as a deficiency condition that was observed to be treatable
with cod liver oil (Wolf, 2004). The theory that diseases were vitamin deficiencies led to
Casimir Funk in 1912 coining the term “vital amines,” vita meaning life and amine from
the compounds he discovered in isolated rice husks (DeLuca, 2014; Wolf, 2004).
Although vitamin D deficiency has been known about for centuries and was written about
by Glisson in 1650, in 1922 vitamin D was discovered as the antirickets factor.
McCollum and co-workers named the antirickets factor the new vitamin D factor (Wolf,
2004).
Hess and Unger in 1921 observed that sunlight was also effective at curing
rickets, which helped explain the evidence of seasonal variation in sunlight as a vitamin
4

D source (Wolf, 2004). Hess, Weinstock, Black, and Steenbock in 1924 observed that
foodstuff (grasses, corn, and olive oil) irradiated with sunlight or ultraviolet (UV) light
became antirachitic, which led to the irradiation of milk fortified with provitamin D2 in
an effort to prevent and eradicate rickets (Holick, 2003). A substance equivalent to the fat
soluble compound, 7-dehydrocholestrol, was isolated in the 1930’s (DeLuca, 2014).
Vitamin D was recognized as a vital amine compound in the early 20th century as the
prohormone known as calciferol. The “sunshine vitamin” comprises a group of fat
soluble secosteroids (Norman, 2008). Vitamin D exists as two major forms, D2
(ergocalciferol) which is consumed in the diet from animal-based foods, fortified foods,
or dietary supplements and D3 (cholecalciferol) which is synthesized in the skin via
ultraviolet B (UVB) radiation (UVB wavelength 290 to 315) (Holick, 2007; MacLaughlin
& Holick, 1985; Morris, 2005).
The structures of vitamin D compounds were determined by Windaus in the
1930s; vitamin D2 was chemically characterized in 1932 and vitamin D3 in 1936 (Figure
2.1). Vitamin D2 is produced by UV irradiation of ergosterol from yeast and D3 by UV
irradiation of 7-dehydrocholesterol from lanolin (Holick, 2007).

Ergocalciferol (Vitamin D2)
Figure 2.1

Cholecalciferol (Vitamin D3)

Structures of Vitamin D2 and D3
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Vitamin D Activation and Metabolism
Vitamin D from sunlight is a biologically inactive prohormone cutaneously
synthesized to 7-dehydrocholesterol resulting in the formation of previtamin D3 and
transformed to active vitamin D3 (Figure 2.2) IOM Food and Nutrition Board, 2011;
Tsiaria & Weinstock, 2011). Extended exposure to sunlight will only convert 10 to 15%
of cutaneous 7-dehydroxycholesterol to previtamin D3 (Tsiaras & Weinstock, 2011).
Vitamin D3 circulation in the body is metabolized by an enzymatic hydroxylation
reaction by 25-hydroxylase in the liver to 25-hydroxyvitamin D (25(OH)D) (Norman,
2008) carried by a CYP enzyme (CYP27B1) (Holick et al., 2011; IOM Food and
Nutrition Board, 2011). The main circulating metabolite, 25(OH)D, enters into systemic
circulation bound to a specific plasma carrier protein, vitamin D binding protein. The
serum concentration peaks 24 to 48 hours after exposure to UV radiation and declines
with a half-life of 36 to 78 hours as it is being taken up by adipocytes and stored in
adipose tissue. This prolongs the half-life of total body serum 25(OH)D levels to
approximately two months (Tsiaras & Weinstock, 2011). Bioavailability of vitamin D is
dependent on intestinal absorption, fat storage in adipose tissue, and metabolism (Tsiaras
& Weinstock, 2011). Absorption of vitamin D occurs in the small intestine with dietary
fats (IOM Food and Nutrition Board, 2011).
The kidneys metabolize 25-dihydroxyvitamin D3 (25(OH)2D) to the hormone
1,25-dihydroxyvitamin D3 (1,25(OH)2D) mediated by 1α-hydroxylase enzyme dependent
on cytochrome P-450 (CYP27B1) (Holick et al., 2011; Urrutia-Pereira & Sole, 2015).
This is the primary step of regulation of 1,25(OH)2D homeostasis which exerts influence
on the expression of the 1α-hydroxylase enzyme (Farrell & Herrmann, 2013). Plasma
6

parathyroid hormone (PTH) levels and serum calcium and phosphate levels regulate this
step (Holick, 2007). The sodium-phosphate co-transporter is initialized by the cells of the
kidney and small intestine and suppresses 1,25(OH)2D synthesis by the fibroblast growth
factor 23 (FGF23) (Holick, 2007). The half-life of 1,25(OH)2D is a few hours (IOM Food
and Nutrition Board, 2011).
The biologically active 1,25(OH)2D is transported in the blood bound to a vitamin
D binding protein, vitamin D receptor (VDR), which is present in the small intestine,
kidneys, and other tissues to transport vitamin D3 to multiple biological targets (Holick,
2007; Holick et al., 2011). This process also occurs in other tissues and cells including
cancer cells, islets cells of the pancreas, and epithelial cells of the colon; in vitro in cells
of the bone, prostate, cerebral cortex, and placenta (Farrell & Herrmann, 2013). More
than 37 vitamin D3 metabolites have been isolated and chemically characterized
(Norman, 2008). Over the years a broader perspective of vitamin D in the tissue
distribution of VDR has shown its response to more than 36 cell types (Norman, 2008).
These metabolites are systemic and transported to distal target organs (Table 2.1). A wide
range of biological actions are exhibited by 1,25(OH)2D, and may be responsible for the
regulation of up to 200 genes responsible for the pleiotropic health benefits of vitamin D
(Holick, 2008; Holick et al., 2011).
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DIET
(fish, fortified food,
supplements)

SKIN
UV exposure
7-Dehydrocholesterol
Previtamin D3

Vitamin D2 and D3

LIVER
25-hydroxyvitamin D
25(OH)D

KIDNEY
1,25-dihydroxyvitamin D
1,25(OH)2D

Vitamin D target cells

Figure 2.2

Vitamin D Metabolism
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Table 2.1

Vitamin D and Tissue Distribution of Vitamin D Receptors

Tissue distribution
Adipose
Muscle, embryonic
Adrenal
Muscle, smooth
Bone
Osteoblast
Bone marrow
Ovary
Brain
Pancreas β cell
Breast
Parathyroid
Cancer cells
Parotid
Cartilage
Pituitary
Colon
Placenta
Epididymis
Prostate
Hair follicle
Retina
Heart
Skin
Intestine
Stomach
Kidney
Testis
Liver (fetal)
Thymus
Lung
Thyroid
Lymphocytes (B and T)
Uterus
Source: Norman, 2008
Vitamin D Metabolism during Pregnancy
Maternal vitamin D and calcium metabolism occur differently during pregnancy
to adapt to fetal requirements by increasing calcium absorption for skeletal development.
The carrier of 25(OH)D from the mother to the fetus is the placenta, which forms at four
weeks of gestation. The fetal cord blood concentration is correlated with the mother’s
serum concentration. The active metabolite, 1,25(OH)2D, is produced by the fetal
kidneys, not transported through the placenta from the mother. Activity of the CYP27B1
in the maternal (decidual) and fetal placental (trophoblastic) synthesize 1,25(OH)2D from
decidual cells (Figure 2.3) (Hossein-Nezhad & Holick, 2013; Lin & Hewison, 2012). The
production of 1,25(OH)2D from 25(OH)D and extra-renal expression of CYP27B1
occurring in the placenta can be inactivated by a 24-hydroxylase mitochondrial
9

cytochrome p450 enzyme, CYP24A1. However, the production of 1,25(OH)2D provides
a negative feedback control to increase vitamin D by two-fold in the third trimester of
pregnancy (Shin et al., 2010).
At the end of the first trimester of pregnancy, the chorioallantoic placenta is
established. The production of 1,25(OH)2D aids in the transformation of endometrial
cells into decidual cells, implantation and normal pregnancy to support fetal growth
through delivery of calcium, and controls secretion of multiple placental hormones (Shin
et al, 2010). The levels of maternal serum 1,25(OH)2D may increase by two-fold
(Mulligan, Felton, Riek, & Bernal-Mizrachi, 2010); an increase of 50 to 100% may be
observed during the second trimester and as much as 100% during the third trimester
(Ponsonby, Lucus, Lewis, & Halliday, 2010; Specker, 2004). Vitamin D synthesized
from the decidual cells of the placenta assists in intrauterine development of the fetus
(Aly et al., 2013). An increase in serum concentration is not clearly understood; however,
synthesis depends on possible increased placental and decidual 1α-hydroxylase activity
and the acceleration of 1α-hydroxylation in the maternal kidneys (Mulligan et al., 2010).
The transfer of calcium and placental synthesis of vitamin D is produced in the
fetal parathyroid and placental tissues by PTH-related peptide (PTHrP), which acts
through the PTH/PTHrP receptor in the kidney and bones during maternal circulation
(Urrutia-Pereira & Sole, 2015). Accumulation of 21 to 30 grams of calcium are provided
to the fetus for bone mineral accretion in the first trimester and doubles in the last
trimester (Lin & Hewison, 2012; Mulligan et al., 2010; Specker, 2004; Urrutia-Pereira &
Sole, 2015).
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Figure 2.3

Pathway for Vitamin D3 during Pregnancy (Lin & Hewison,
2012). Permission was given to use this copyrighted diagram from
Elsevier.

Sources of Vitamin D
Vitamin D (D2 or D3 or both) can be obtained from exposure to sunshine, diet, or
supplements (Holick, 2007). Vitamin D exposure to the skin without sunscreen produces
10 times more vitamin D than the vitamin D content in most foods. Exposure between 10
AM and 3 PM twice a week for 5 to 30 minutes is often adequate (Seber, 2014).
Exposure to one minimal erythemal dose (MED) of UV radiation is equivalent to
ingesting between 10,000 and 25,000 IU of vitamin D (Holick et al., 2011). Produced in
11

the skin compared with ingestion, vitamin D may last at least twice as long in the blood
(Holick et al., 2011).
Some foods naturally contain vitamin D while some foods and supplements are
fortified (Table 2.2). Fish such as salmon, tuna, and mackerel are good sources of vitamin
D. Vitamin D2 (ergocalciferol) is found in vegetal sources such as sun-exposed yeast and
mushrooms. Other fortified foods permissible in the United States are farina, rice,
cornmeal, noodle and macaroni products, soy beverage products, soy-based butter
substitute spreads, calcium fortified 100% fruit juices and fruit juice drinks, and meal
replacements such as fortified drinks and bars (Calvo & Whiting, 2013). Staple items
using wheat flour fortified with vitamin D was reported to be useful in the United
Kingdom to increase vitamin D status (Allen, Dangour, Tedstone, & Chalabi, 2015).
Approximately 60% of vitamin D intake in the United States and Canada is from fortified
foods (Calvo & Whiting, 2013).

12

Table 2.2

Vitamin D Sources and Content
Source

Vitamin D3 or D2 content
International Units (IU)

UV exposure
Exposure to sunlight, UVB (0.5 MED)
Full body UV exposure

3000 D3
3,000-20,000

Foods
Salmon, fresh, wild (3.5 oz)
Salmon, fresh, farmed (3.5 oz)
Salmon, canned (3.5 oz)
Sardines, canned (3.5 oz)
Mackerel, canned (3.5 oz)
Tuna, canned (3.6 oz)
Cod liver oil (1 tsp)
Shiitake mushrooms, fresh (3.5 oz)
Shitake mushroom, sun-dried (3.5 oz)
Egg yoke

600-1000 D3
100-250 D3 or D2
300-600 D3
About 300 D3
About 250 D3
About 230 D3
About 400-1000 D3
About 100 D2
1600 D2
About 20 D3 or D2

Fortified Foods
Fortified milk (8 oz)
Fortified orange juice (8oz)
Fortified butter (3.5 oz)
Fortified margarine (3.5 oz)
Fortified yogurts (3.5 oz)
Fortified cheeses (3 oz)
Fortified breakfast cereals per serving
Infant formulas (8 oz)

100 D3
100 D3
50 D3
430 D3
100 D3
100 D3
100 D3
100 D3

Supplements
Prescription
Vitamin D2 (ergocalciferol)
50,000 IU/capsule
Drisdol (vitamin D2 liquid
8000 IU/ml
supplement)
Over the counter
Multivitamin
400 vitamin D, D2 or D3
Vitamin D3
400, 800, 1000, and 2000, IU
Note: UVB (Ultraviolet radiation); MED (minimal erythemal dose)
(Holick, 2007)
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Vitamin D Status during Pregnancy
Vitamin D status based on serum 25(OH)D concentrations has been defined as
risk of deficiency, risk of inadequacy, sufficiency, and no reason for concern according to
the IOM Food and Nutrition Board (2011). Serum 25(OH)D concentrations of <12
ng/mL (<30 nmol/L) are defined as deficiency, 12-19 ng/mL (30-49 nmol/L) are
inadequate levels, >20 ng/mL (>50 nmol/L) are sufficient levels, and levels >50 ng/mL
(125 nmol/L) are possibly harmful. In pregnancy, 25(OH)D serum level
recommendations vary with a suggestion of 20 ng/ml (50 nmol/L) by IOM Food and
Nutrition Board (2011) and 30 ng/ml (75 nmol/L) or more by the Endocrine Society
(Mithal & Kaira, 2014). Inconsistencies exist with an optimal level not defined for health
(Bischoff-Ferrari, Giovannucci, Willett, Dietrich, & Dawson-Hughes, 2006) creating a
concern for the appropriate vitamin D requirement.
The prevalence of vitamin D deficiency during pregnancy is a major health
problem and a worldwide growing concern among the general population.
Recommendations for vitamin D intakes have been provided for pregnant and lactating
women; however, recommendations vary with different sources (Table 2.3). The IOM
and the National Institute for Health and Care Excellence (NICE) in the United Kingdom
give daily recommendations for vitamin D for pregnant and lactating women as 600
IU/day (Maladkar, Sankar, & Kamat, 2015). According to a study by Hollis and Wagner
(2005), this recommendation does not increase vitamin D status among women and
lactating women, especially among African Americans, and is irrelevant. The usual
amount in prenatal vitamins for pregnant women is 400 IU. The Endocrine Society
recommends 1500 to 2000 IU/day (Hollis & Wagner, 2013) and the American College of
14

Obstetricians and Gynecologists suggests dosages up to 1000 to 2000 IU/day as safe for
pregnant women who are deficient in vitamin D (Holick et al., 2011). Using the IOM cut
off points and taking prenatal vitamins containing 400 IU of vitamin D, 7% of pregnant
and 21% of lactating women were at risk for vitamin D deficiency (<12 ng/L) or
inadequacy (<20 ng/L) (Urrutia & Thorp, 2012). The Canadian Pediatric Society gave a
recommendation of 2000 IU/day for pregnant and lactating women (Table 2.3) (Maladkar
et al., 2015).
Table 2.3

Vitamin D Recommendations for Pregnant and Lactating Women from
Various Sources

American
Congress of
Obstetricians &
Gynecologists
(ACOG)

National
Institutes for
Health and
Care Excellence
(NICE)
United Kingdom

IU/d

IU/d

1000-2000

600

Institute of
Medicine
(IOM)
EAR
(IU/d)

400

RDA
(IU/d)

600

UL
(IU/d)

4000

Canadian
Pediatric
Society

IU/d

2000

Endocrine Society
Practice
Guidelines
Committee
IU/d

15002000

UL/d

10000

Note: EAR (Estimated Average Requirement), RDA (Recommended Dietary
Allowance), UL (Tolerable Upper Intake Level), UL (Upper Intake Level)
Optimal serum 25(OH)D levels are not clearly defined for pregnant and lactating
women to prevent deficiencies. Figure 2.4 presents the vitamin D status of less than 30
nmol/L, less than 50 nmol/L, and less than 75 nmol/L for pregnant and lactating women
worldwide. A measure of 25(OH)D serum concentrations may vary according to the
reproductive stage. Several studies reported vitamin D deficiency occurring in more than
90% of pregnant women taking prenatal vitamins (Emadi & Hammoudeh, 2013).
Prevalence of vitamin D deficiency ranged from 18% to 84% depending on the country
and customs associated with the location (Mulligan et al., 2010). Johnson et al. (2011)
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reported the prevalence of vitamin D deficiency (25(OH)D levels <20 ng/mL) among
pregnant women as 97% in African Americans, 81% in Hispanics, and 67% in
Caucasians. Both African American and white childbearing-age women in the United
States were three times more likely to be vitamin D deficient in winter than summer
(Bodnar, Simhan et al., 2007).

Figure 2.4

Vitamin D Status among Pregnant or Lactating Women Worldwide
(Palacios & Gonzalez, 2014). Permission was given to use this copyrighted
diagram from Elsevier.
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The prevalence of vitamin D deficiency worsens at latitudes above 37° in winter
months (November through March) (Figure 2.5) and in individuals with darker skin
pigmentation (Holick, 2007). Maternal vitamin D deficiency at or near term for darkskinned or veiled populations in various latitudes ranged from 30% to 70%, for light
skinned populations it was 5% to 20% (Dror & Allen, 2010). A study by Hamilton et al.
(2010) of a diverse group of pregnant women in South Carolina at latitude 32° N
indicated overall that 48% of the participants were deficient and 37% had insufficient
levels of vitamin D. The 25(OH)D levels below 30 nmol/l among pregnant women was
59% to 84% in the Dutch and 10% to 30% in Greece, the Netherlands, and Belgium
(Bischoff-Ferrari, 2011). Vitamin D prevalence is especially high in Asia, ranging from
18% to 80% (Yang et al., 2015).

Figure 2.5

Latitudes Above and Below 37° N in the United States for Adequate
Vitamin D Concentrations (Holick, 2007). Permission was given to use this
copyrighted diagram from Harvard Health Publishing.
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The greatest prevalence of low levels of vitamin D are usually among African
Americans and Hispanic women. A study of mother-infant pairs reported by Bodnar,
Catov, Roberts, and Simhan (2007) indicated more that 50% of mothers and newborns
had vitamin D insufficiency among 200 whites and 200 African Americans. In the United
States, two out of three pregnant women had suboptimal vitamin D status with higher
prevalence among African Americans and Mexican American women (Looker, Pfeiffer,
Schleicher, Picciano, & Yetley, 2008). Low levels of vitamin D were estimated to occur
in 5% to 50% of pregnant women (Mulligan et al., 2010). Bodnar et al. (2007) indicated
that vitamin D insufficiency among black and white pregnant women residing in the
northern United States was 74% to 95% and 46% to 62% respectively, resulting in the
neonates having vitamin D deficiency of 9.7% in African Americans and 5.0% in whites.
The fetus is affected by vitamin D deficiency in pregnant women with the status
depending on dietary intake, vitamin D stores, supplementation, and sunlight exposure.
Maternal response to calcium demands of the fetus are provided by adequate vitamin D
concentrations. The umbilical cord blood concentration of 25(OH)D ranged between 68%
and 108% of the maternal 25(OH)D levels at the time of delivery. A measure of cord
blood levels in African American infants was lower than whites (Basile, Schmedes,
Manscbach, & Camargo, 2007). Cord blood vitamin D levels among newborns showed a
high prevalence of vitamin D deficiency among participants of different ethnicities, skin
color, and maternal supplementation in a study by Cadario et al. (2013). Vitamin D levels
in cord blood were significantly higher in newborns with fair skin than those with dark
skin regardless of maternal vitamin D supplementation (Cadario et al., 2013).
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Obesity also affects vitamin D status. Wortsman, Matsuoka, Chen, Lu, and Holick
(2000) reported that obese individuals were prone to vitamin D deficiency. Excess body
fat may cause a sequestering of vitamin D in adipose tissue that reduces its bioavailability
for metabolic activation (Wortsman et al., 2000). Maternal obesity affects vitamin D
status in newborns. Infants born to obese mothers had significantly lower cord blood
25(OH)D levels compared to infants from normal weight mothers (Josefson et al., 2013).
It was concluded that obese women transferred less 25(OH)D to their fetuses than normal
weight women, which occurred when the two groups of women had similar serum levels
of 25(OH)D (Josefson et al., 2013). Bodnar, Catov, Roberts, and Simhan (2007) reported
that maternal obesity was strongly associated with neonate vitamin D deficiency and
concluded that maternal and newborn vitamin D deficiency is a serious public health
problem.
Vitamin D and Possible Outcomes Associated with Deficiency
Maternal vitamin D deficiency has been associated with adverse outcomes in
pregnancy. A low level of plasma 25(OH)D among non-pregnant women puts them at
risk during pregnancy. Table 2.4 indicates the levels of vitamin D in women with serum
25(OH)D levels of 32 ng/mL or greater are required to achieve adequate calcium and
parathyroid hormone levels. These 25(OH)D levels have been suggested to apply to
pregnancy and lactation (Mulligan et al., 2010).
The pleiotropic effects of Vitamin D in its influence on growth, differentiation,
and optimal functions of cells may account for associations of vitamin D deficiency with
a number of health complications. Pregnancy complications are related to preconception,
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maternal, prenatal, neonatal, and child health complications (Bischoff-Ferrari, 2011;
Enquobahrie, Williams, Qui, Siscovick, & Sorensen, 2011).
Vitamin D plays a role in the process of reproductive success with high levels of
25(OH)D in serum and follicular fluid in in vitro fertilization techniques. Studies
involving the potential role of vitamin D deficiency in conception and fertility in people
have yet to be investigated with most studies involving animal models. Vitamin D
deficient animal models exhibited a reduction in fertility and litter size, 75% and 30%,
respectively, and the CYP27B1 (1-α hydroxylase) models were infertile (Lewis, Lucas,
Hallliday, & Ponsonby, 2010).
Table 2.4

Vitamin D Levels and Adverse Effects

Serum 25(OH)D (ng/mL)
<10

Deficient

11-32

Inadequate

32-100

Sufficient

>100

Possibly
harmful

Mulligan et al., 2010

Maternal adverse effects

Increased risk of preeclampsia
Calcium malabsorption
Bone loss
Poor weight gain
Myopathy
Higher parathyroid hormone level
Bone loss
Subclinical myopathy
Adequate calcium balance
Parathyroid hormone levels
Hypercalcemia
Increased urine calcium loss

Pregnancy complications such as pre-eclampsia, caesarean section, and
gestational diabetes are associated with maternal vitamin D deficiency (Figure 2.6)
(Kaushal & Magon, 2013; Lin et al., 2011). The onset of pre-eclampsia in early
pregnancy was associated with low vitamin D levels among women that eventually
developed pre-eclampsia, which increased the risk of maternal mortality and neonatal
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morbidity or mortality for mother and fetus (Robinson, Alanis, Wagner, Hollis, &
Johnson, 2010). Pre-eclampsia, a disorder involving dysregulated placental
vascularization and hypertensive disorders affects up to 10% of pregnancies (Lin et al.,
2011; Mulligan et al., 2010). In the United States, 15% of preterm births are contributed
to early onset severe pre-eclampsia (Robinson et al., 2010). The United States birth rate
by caesarean section was 30.2% (Merewood, Mehta, Chen, Bauchner, & Holick, 2009).
Caesarean section was four times more common in women with Vitamin D deficiency,
which was defined as less than 37.5 nmol/L, compared to women with normal levels
(Merewood et al., 2009). Fetal bone development from decreased skeletal mineralization
in utero may result in rickets among newborn infants (Specker, 2004). Child health
complications from vitamin D insufficiency have been linked to type 1 diabetes, multiple
sclerosis, and respiratory infection (Ginde, Sullivan, Mansbach, & Camrgo, 2010).

Pregnancy

Preconception
In vitro fertilization

Maternal:

Maternal:

Fetal:

Fetal:

Pre-eclampsia
Gestational diabetes
Bacterial vaginosis
Bone health
Insulin resistance
Bone development delay

Figure 2.6

Perinatal

Caesarean delivery

Body size and shape reduced
Bone defects
Poor skeletal mineralization

Possible Outcomes of Vitamin D Deficiency (Lewis et al., 2010;
Urrutia-Pereira, & Sole, 2015; Principi, Bianchini, Baggi, &
Esposito, 2013; Ponsonby et al., 2010)
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Vitamin D Supplementation Before and During Pregnancy
The optimal dose of vitamin D supplementation depends on many factors
including race/ethnicity, sunlight exposure, dietary intake, absorption, and metabolism.
The use of supplements in the non-pregnant population has been examined in correlation
with 25(OH)D levels with a recommended level of 75 to 80 nmol/L as sufficient.
Supplementation of 1800 to 4000 IU per day of vitamin D was suggested to maintain
levels of 75 to 110 nmol/L serum 25(OH)D (Ponsonby et al., 2010).
The use of vitamin D supplementation to acquire the optimal level of 25(OH)D
during pregnancy has not been clearly defined (Lapillonne, 2009) and routine monitoring
of 25(OH)D levels does not occur (Ponsonby et al., 2010). Prenatal vitamins are
generally supplemented with 400 IU vitamin D. The IOM recommends 600 IU/day as the
Recommended Dietary Allowance (RDA) for pregnant and lactating women.
Vitamin D supplementation in pregnancy has been reported in RCTs to support
the need and benefit of increasing vitamin D status. A study by Taheri, Baheiraei,
Foroushani, and Modarres (2014) indicated that 2000 IU/day improved vitamin D status
in reproductive women in Iran given supplements 15 weeks in the preconception period.
Excessive supplementation can lead to vitamin D intoxication and related hypercalcemia
and hypercalciuria. Diagnosis of vitamin D intoxication shows an increase of 25(OH)D
concentration with normal levels of 1,25(OH)2D and with PTH suppressed (Vogiatzi,
Jackson-Dickman, & DeBoer, 2014). Increasing usage of vitamin D supplements may
result primarily in hypercalcemia with vitamin D toxicity at a level greater than 50 ng/mL
(Dudenkov et al, 2015). Looker et al. (2011) indicated that levels particularly above 60
ng/mL (>150 nmol/L) caused adverse effects.
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A meta-analysis using RCTs of vitamin D supplementation reported that
maternal/cord serum concentrations of 25(OH)D increased but the dose-response effect
was weak (Roth et al., 2017). Yang et al. (2015) reported cord blood 25(OH)D
concentration was significantly increased by maternal supplementation of vitamin D in a
meta-analysis using RCTs. The proportion of pregnant women given high doses of
vitamin D (> 3000 IU/day) that reached a 25(OH)D level of 20 ng/ml or higher was 80%
to 90% in a meta-analysis using RCTs (Chakhtoura et al., 2017). A meta-analysis
conducted by Palacios, De-Regil, Lombardo, and Pena-Rosas (2016) concluded that
vitamin D supplementation in pregnant women significantly increased serum 25(OH)D
levels at term compared to placebo/control but results were inconsistent. Perez-Lopez et
al. (2015) concluded that serum 25(OH)D levels in pregnant women were higher with
vitamin D supplementation, and their babies had higher birth weights and lengths
compared to the controls. A meta-analysis by Thorne-Lyman and Fawzi (2012) revealed
a significant reduction in the risk of low birthweight infants by pregnant women given
vitamin D supplementation; however, their meta-analysis used a combination of RCTs
and observational studies. A recent meta-analysis also using RCTs and observational
studies concluded that vitamin D supplementation during pregnancy reduced the risk of
preterm birth (Zhou, Tao, Huang, Xhu, & Tao, 2017).

Systematic Review and Meta-Analysis Review
A systematic review compiles all relevant studies aimed to collate and synthesize
data using methods that attempt to minimize bias (Higgins et al., 2011). An extensive
search of online databases using pertinent keywords is conducted. Other sources may also
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be hand searched such as reference lists of published reviews. Systematic reviews are
important in health care to provide evidence from specific research in reviewing
published literature to focus on specific topics. The empirical evidence of a systematic
review follows criteria to answer a specific research question which may or may not
include a meta-analysis (Haidich, 2010). Relevant studies are identified from an
extensive search and the quality of each study is assessed. The assessment of the quality
of studies should include: (1) research question; (2) study selection criteria in identifying
relevant studies; (3) minimum acceptable level of design in extracting relevant data on
outcomes and quality; (4) summary of the evidence; and (5) interpreting of the findings
(Khan, Kunz, Kleijnen, & Antes, 2003). Guidelines have been published for conducting
and reporting results for systematic reviews and meta-analyses, which is the Preferred
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement
(Liberati et al, 2009).
Meta-analysis is a type of systematic review of which data are quantitatively
compiled and statistically analyzed. Several studies are combined into a single
quantitative estimate, or summary effect size. An effort to reduce bias is accomplished by
identifying, appraising, and synthesizing relevant studies on a particular topic (Uman,
2011). A meta-analysis utilizes the sample sizes and other statistical data, such as
pre/post results of interventions, from independent studies to estimate the effect
(Akobeng, 2005; Haidich, 2010). Similar studies should be combined in a meta-analysis
to measure the treatment effect with the 95% confidence interval (CI) of each study.
Studies are summarized into an overall summary estimate, or effect size (Akobeng,
2005). The participants, intervention, and setting should be similar to obtain an overall
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estimate of the effect of the intervention. RCT studies tend to be similar in their design.
Additionally, RCTs are the most trusted primary types of evidence (Choong & Tsafnat,
2012). These studies are quantitative, comparative, controlled experiments. The effect of
the interventions on particular outcomes is examined by randomizing participants to
receive or not receive an intervention.
A meta-analysis may consist of three main parts after combining all the studies.
These are (1) overall pooled estimates and CIs for the treatment and control groups, (2) a
test to determine if the treatment or risk factor is statistically significant, and (3) a test for
heterogeneity among the included studies, which tests for how similar or dissimilar the
studies are to each other. Heterogeneity indicates how comparable the studies are to each
other in a meta-analysis (Ried, 2006).
Forest and funnel plots graphically present the results of a meta-analysis. A forest
plot (or CI plot) displays the effect estimates (effect sizes) with the CIs for each study
that was selected to be included in the meta-analysis. The effect size is shown for each
individual study in the meta-analyses with an overall summary effect presented on the
bottom of the plot. The forest plot provides an overall statistical view to determine if the
intervention or the control is favored by the location of the diamond on the bottom of the
plot. Funnel plots (or scatter plots) display effect size versus standard error indicating the
difference or heterogeneity between groups in the studies of the overall results (AnzuresCabrera & Higgins, 2010; Higgins et al., 2011).
Heterogeneity is common in meta-analyses and should be statistically evaluated.
Cochran’s Q test is traditionally used and is based on the χ2 test. A significant Q value
would indicate whether heterogeneity existed among the sample estimates (effect sizes)
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and variation occurred, which was not due to sampling error. Significant heterogeneity
between studies is indicated with a large Q value (Berman & Parker, 2002). The I2 value
is also usually reported because it quantifies the heterogeneity. I2 values range from 0%
(no heterogeneity) to 100% (extreme heterogeneity). Higgins and Green (2008a)
described I2 values of 0% to 40% as not important for indicating heterogeneity, 30% to
60% as moderate heterogeneity, 50% to 90% as substantial heterogeneity, and 75% to
100% as considerable heterogeneity occurring in the meta-analysis. Higgins, Thompson,
Deeks, and Altman (2003) defined low, moderate, and high heterogeneity as I2 values of
25%, 50%, and 75%, respectively. Heterogeneity can also be observed visually in a metaanalysis from the graphical view of the forest plot. Heterogeneity is less likely to occur
when the CIs overlap and likely to be significant when there is little or no overlap among
the CIs in the forest plot (Rao et al., 2017).
A high amount of heterogeneity in a meta-analysis can be influenced by studies
that are statistical outliers. Viechtbauer and Cheung (2010) recommended examining the
effect sizes in a meta-analysis for potential outliers. Hedges and Olkin (1985) and
Thomas, Nelson, and Silverman (2011) also discussed outliers in meta-analysis.
Agreement is lacking on how outliers should be handled in a meta-analysis. Some
researchers remove outliers while others do not omit them from the meta-analysis.
Outliers usually add a high amount of variation between the studies in a meta-analysis
and results in a high I2 value. Israel and Richter (2011) reported a meta-analysis may not
be appropriate when study results vary but also noted there are no accepted guidelines for
when a meta-analysis should not be completed due to heterogeneity. There is agreement
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that when heterogeneity exists, a subgroup analysis should be conducted with moderators
that may be expected to contribute to variation among the studies in the meta-analysis.
Publication bias in meta-analysis is a concern because not all completed studies
are published, and the process of selecting studies for publication is not random, which
can be a source of bias. Studies that report significant findings and large treatment effects
may be more likely to be published than studies with null findings. If there is a biased
collection of studies in a meta-analysis, then the overall treatment effect would tend to be
overestimated. It is important to assess the existence and amount of publication bias in a
meta-analysis, which can be done by the use of several tests, including visually
inspecting the funnel plot for symmetry, and Classic fail safe N and Duvall and
Tweedie’s trim and fill tests (Borenstein, Hedges, Higgins, & Rothstein, 2009).
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CHAPTER III

METHODOLOGY
A systematic review and meta-analysis were conducted following the PRISMA
statement for reporting, screening, and selecting studies as outlined in the guidelines and
checklist (Liberati et al., 2009). The PRISMA checklist outlines the items to be included
in a systematic review and meta-analysis (Appendix A). The characteristics of the study
design followed the PICOS format: identifying the participants/population (P), type of
intervention (I), control group (C), outcomes (O), and study design (S) (Moher, Liberati,
Tetzlaff, Altman, & The PRISMA Group, 2009) (Appendix B). The
participants/population defines the specific characteristics of interest and the setting or
care provided to the group. The type of intervention addresses the specific exposure that
the participants obtain that may create a change in their status. An intervention may be
shown to be beneficial or not beneficial to the status of the participants compared to a
control group not given the intervention. Outcomes or results of the intervention can be
used to determine the need to change the status of the individuals. The PICOS statement
(research question) for this study was: Will RCTs that include vitamin D supplementation
interventions in pregnant women have a significant effect on their vitamin D status and
pregnancy outcomes?
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Research Design and Rational
Vitamin D is important in the health of each individual. Low levels can result in
unwanted health conditions. Vitamin D deficiency is common during pregnancy with
high risk groups such as women with limited sun exposure, ethnic minorities, and
vegetarians. Although vitamin D levels are readily achieved by sunlight, many areas have
limited sunlight availability, or women do not expose themselves to sunlight, and
supplementation is needed to increase the levels. Adequate vitamin D concentrations are
necessary in pregnancy and may help to improve the vitamin D status during fetal and
newborn stages (Kaushal & Magon, 2013). Supplementing pregnant women increases
25(OH)D at delivery but outcomes are inconsistent and questionable for the appropriate
level to minimize effects (Wagner, Taylor, Johnson, & Hollis, 2012). Much controversy
on the acceptable amount of supplementation has led to clinical trials trying to determine
the effects of vitamin D on health. Recommendations on vitamin D supplementation from
evidence based studies can provide information on serum 25(OH)D levels that are
beneficial to improve the outcomes of pregnant women from varied ethnicities in
different regions of the world.
This systematic review and meta-analysis focused on vitamin D supplementation
and vitamin D serum levels associated with pregnancy outcomes. The objective of this
systematic review of RCTs was to provide relevant information on vitamin D status in
pregnant women, especially those at risk for low vitamin D. This review examined
vitamin D supplementation during pregnancy to determine acceptable ranges to improve
the health status for the mother, fetus, and health of the newborn. The objective of the
meta-analysis of RCTs was to examine the duration of exposure with vitamin D
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supplementation and compare the outcomes to those who did not take supplement. Data
were statistically analyzed to observe the effect of supplementation on vitamin D status.
The following specific objectives for this study were to (1) systematically identify
studies targeting vitamin D status during pregnancy that focus on risk factors associated
with the target population and increase vitamin D status, (2) observe the amount of
vitamin D supplementation that will improve outcomes for mother and infant and not put
them at risk for high or toxic levels of vitamin D, and (3) provide an up-to-date
systematic review and meta-analysis of vitamin D supplementation during pregnancy and
associated health outcomes.
The studies chosen were RCTs of pregnant women given vitamin D
supplementation; many of the women were at risk for low vitamin D status or vitamin D
deficiency. Low vitamin D status among this population of women included the risk
factors of darker skin pigmentation, limited sunlight exposure, and inadequate dietary
intake of vitamin D. Supplements to increase vitamin D status were given to participants
in the treatment groups and compared to the control or placebo groups.
Search Procedure
An extensive literature search was conducted in PubMed, Scopus, ProQuest,
EBSCO, Cochrane CENTRAL Database of Controlled Clinical Trials, PsycINFO,
CINAHL, and Google Scholar to compile a comprehensive list of RCTs of vitamin D
status/deficiency and supplemental use in pregnancy and outcomes. Search criteria
included all journal articles that resulted from combinations of keywords, title word, or
heading searches for “Vitamin D,” “supplementation,” “pregnant,” “pregnancy,”
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“maternal vitamin D,” and “randomized control trials.” Reference lists of literature
reviews and systematic reviews were also hand searched.
Study Inclusion and Exclusion Criteria
Studies in the systematic review and meta-analysis met the following inclusion
criteria:
1. Randomized controlled trial
2. Vitamin D supplementation interventions performed with pregnant women
3. Vitamin D alone or in combination with other micronutrients
4. Baseline measures of serum 25(OH)D status
5. Post intervention measures of 25(OH)D status at gestation week or
delivery
6. Intervention outcome was compared against a control condition
7. Blinded and open label studies. RCTs may not have explicitly stated they
were blinded, but sufficient information may be given to make the
researcher and participants unaware of the treatment.
8. All published studies that can be located and reported in the English
language
9. Year of publication was not a consideration
Studies excluded had the following attributes:
1. Studies not truly randomized such as semi-randomized or quasirandomized or not explicitly stated as being randomized
2. Observational studies
3. Cross-sectional studies
4. Prospective and case-control studies that did not meet criteria for reporting
baseline and post intervention serum 25(OH)D values
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5. Not published in English
6. No assessment of an outcome relevant to vitamin D status
Study Selection and Data Extraction
Study selection involved all applicable citations in the search strategy screened by
titles, abstracts, and full-text articles. The studies identified were reviewed for
information and data extracted from each study included participants’ characteristics
unique to the investigation of vitamin D status during pregnancy. The following
information was extracted from each selected study and compared to inclusion and
exclusion criteria before making a determination to use it in the meta-analysis:
1. First author’s last name and year of publication
2. Location where study was conducted
3. Study design
4. Participants
5. Age of participants
6. Length of intervention
7. Type of intervention
8. Baseline or initial vitamin D status
9. Post vitamin D status
10. Main outcome/results
Data extraction for each included study was reviewed by a second individual. A
data extraction form was utilized for each individual study to obtain relevant information
(Appendix C).
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Assessment of Risk of Bias
Risk of bias in randomized controlled designs can affect the intervention by being
underestimated or overestimated in the available data that are presented. The cumulative
evidence for interventions may be missing studies (publication bias) or missing data
(selective reporting bias) to create differences in the risks of bias (Higgins et al., 2011).
The Cochrane Collaboration’s tool for assessing risk of bias is utilized to determine the
quality of RCTs (Higgins et al., 2011). Studies that are blinded will reduce selection,
performance, and detection bias. The detection bias may include discovery of group
assignment by participants or researchers, which may influence the results. The overall
risk of bias within or across studies can be summarized by information that indicates if
the study has a low, high, or unclear risk of bias. Low risk would include a well-designed
RCT with blinding and strong internal validity, high bias RCTs would include not using
randomization for group assignment and non-blinding, which may influence the
participants’ knowledge of the intervention received. Studies not reporting all of the
components of the RCT such as how participants were recruited or randomization
methods would indicate unclear risk of bias. Assessment of risk of bias can be reported in
one of three strategies: (1) restrict the meta-analysis to low risk studies, (2) stratify
according to risk of bias, or (3) present all studies and provide a summary of risk of bias
across studies, which may lead to possible evidence that is flawed (Higgins et al., 2011).
Measure of Effect Size
The measure of effect size summarizes the findings from specific areas of
research. Effect size quantifies the effectiveness of an intervention by expressing the
magnitude of the association between two variables (experimental and control groups).
33

The significance of a test assists in rejecting or retaining the null hypothesis based on the
p value of the test statistic. A large effect size contributes to high power and a small
effect size indicates low power. The effect size estimates the efficacy and summary
correlation coefficients, differences in means, odds ratios, or rate ratios (Jacobson, 2012).
The standardized mean difference, or the effect size, between two groups is defined by
the following equation:
d = M1 – M2 / SDpooled

(2.1)

The d is Cohen’s coefficient, M is the mean (M1 is the mean of the experimental group
and M2 is the mean of the control group), SDpooled is the pooled standard deviation of both
groups. The computed effect size of each study is combined to achieve the estimate of the
“true effect” of the weighted summary effects of all included studies in the meta-analysis.
An effect size can be interpreted as small if the value of d is .2 or less, medium as .5, and
a large effect size is .8 or greater (Cohen, 1988).
Studies with one control group and multiple treatment groups are a concern in
meta-analyses. The effect sizes will not be independent if the same individuals (the
control group sample size entered into the meta-analysis) is used as a comparison for
more than one treatment group. The number of individuals in the control group would be
misrepresented (over-counted). To avoid this, studies with multiple treatment groups
were pooled and calculated as one treatment as recommended by Borenstein et al. (2009).
The preferred method is to treat the studies compiled in a meta-analysis as separate and
independent of each other so each study will provide unique information. The distribution
of effects in the random effects estimates (the effect sizes) and confidence intervals
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address the question “what is the best estimate of the average effect?” (Higgins & Green,
2008b, p. 370).
Statistical Analysis
The approach in combining data in a meta-analysis can be of two types, fixed
effect model or random effects model, in considering to what extent results are
consistent. The model chosen will affect the interpretation of the summary estimate. The
fixed effect model creates a pooled estimate in the variability of the results with
individual studies weighted by their precision. There is a weighted average of effect sizes
from the series of studies (Haidich, 2010). The studies are assumed to estimate the same
treatment effect which will show no between study heterogeneity. Estimates of the
treatment effect would vary by chance differences from the intervention (Riley, Higgins,
& Deeks, 2011). Heterogeneity reported as I2 measures the variation between studies in
the outcome rather than chance for between study heterogeneity, which would be 0% for
the fixed effect model (Riley et al., 2011).
The random effects model varies across studies in the estimates of treatment
effect (Riley et al., 2011) requiring a test of heterogeneity (Khoshdel, Attia, & Carney,
2006). The heterogeneity in treatment effects can arise from differences in interventions
received, follow-up length, and populations (Riley et al., 2011). When variation exists,
the study is considered as being heterogeneous. An I2 value is computed to test the
amount of variation (Equation 2.2, df is degrees of freedom, Q is the χ2 statistic).

(2.2)
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The Comprehensive Meta-Analysis (CMA) software program (Comprehensive
Meta-Analysis Version 2, 2005, Biostat, Inc., Englewood, NJ) was used for all statistical
analyses. A significance level of .05 was used for all analyses. Individual and summary
effect sizes, heterogeneity, and forest and funnel plots were generated by CMA to
determine the effectiveness of this meta-analytic study.
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CHAPTER IV

RESULTS AND DISCUSSION
Study Selection and Description of Studies
A systematic review and meta-analysis were conducted following the PRISMA
statement criteria shown in Appendix A (Liberati et al., 2009). Each study included in the
meta-analysis was systematically checked based on the criteria. Information from each
study is listed in Appendix B which includes relevant bibliographical information, the
study design, sample size, length of study, age group, intervention type, pre/post data and
main outcome. The publication years ranged from 2011 to 2016. A total of 19 studies met
all the inclusion criteria; however, three studies were later determined to be outliers and
not included in the final meta-analysis (Figure 4.1), which is discussed later in this
chapter. The attributes of the studies in the meta-analysis are described as follows:
Country of origin. The final meta-analysis contained 16 studies which
represented four geographical regions: North America (United States), Europe (United
Kingdom), Australia, and Asia (Iran, Bangladesh, India). Ten studies were conducted in
Iran, two in the United States, one in Australia, one in Bangladesh, one in India, and one
in the United Kingdom.
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Duration of study. Studies were conducted from a minimum of 6 weeks (Asemi,
& Karamali, 2014) to a maximum span of ongoing interventions of six years (Cooper et
al., 2016).
Study participants. A total of 3908 participants were recruited and 2927
completed the interventions from the 16 studies included in the final meta-analysis.
Participants ranged from mean ages of 22 to 32 years of age. A total of seven studies
(Asemi et al., 2016; Cooper et al., 2016; Hollis, Johnson, Husley, Ebeling, & Wagner,
2011; Mir et al., 2016; Sabet, Ghazi, Tohidi, & Oladi, 2012; Soheilykhan, Mojibian,
Moghadam, & Shojaoddiny-Ardekani, 2013; Wagner et al., 2013) observed vitamin D
status of healthy pregnant women. Vitamin D status was observed for one study of
healthy pregnant women and depression (Variz et al., 2016). A combination of vitamin D
supplementation and calcium was observed in three studies (Asemi, Samimi, Tabassi, &
Ahmad 2014; Karamali, Asemi, Ahmadi-Dastjerdi, & Esmaillzadeh, 2016). Three studies
(Asemi & Esmaillzadeh, 2015; Karamali, Beihaghi, Mohammadi, & Asemi, 2015;
Samimi et al., 2016) included a multi-mineral supplement with vitamin D. Five studies
did not report the use of a multivitamin.
Studies selected for the meta-analysis were reviewed by two individuals based on
the inclusion and exclusion criteria. Studies included in the meta-analysis were evaluated
for study content of research design, pre (baseline)/post intervention data and other
relevant information. Data of pre (baseline)/post interventions were reported as means
and standard deviations from each study (Appendix C).
The final review of studies selected 19 studies to be included in the meta-analysis
(Figure 4.1). The studies assessed various dosages of vitamin D supplements given to
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pregnant women from the first, second, or third trimesters to delivery. These studies
included single/multi-center RCTs, double/single blinded, and non-blinded studies.
Among the studies, the primary or secondary aim was focused on the effectiveness of
vitamin D supplementation in pregnancy and safety at high dosage. In general, baseline
serum 25(OH)D concentrations and levels at delivery indicated the need for
supplementation to improve vitamin D status during pregnancy. Although the studies did
not directly investigate the requirement for vitamin D during pregnancy, the metaanalysis included studies that were investigating other outcomes during pregnancy but
would likely affect the serum 25(OH)D concentrations at delivery. Additional outcomes
associated with vitamin D supplementation (and calcium) and multi-mineral vitamin D
supplementation focused on metabolic status for pregnant women with gestational
diabetes mellitus (GDM) or at risk for pre-eclampsia, depression, and neonatal outcomes.
RCTs that were excluded from the meta-analysis did not provide adequate information or
data were missing, which prohibited the calculation of treatment effects (Appendix D).
Attempts to contact a corresponding author to ask for additional results of a study were
unsuccessful.

39

Included

Eligibility

Screening

Identification

4568 records identified
through
database searching

Figure 4.1

5 additional records
identified through other
sources

288 records after titles/abstracts and
duplicates removed

105 records
screened

35 full-texted articles
assessed for eligibility

19 studies included in the initial
quantitative synthesis (metaanalysis), 3 studies were determined
to be outliers and removed.
16 studies included in the final metaanalysis

Flow Chart for Identification and Selection of Studies for the
Meta-Analysis
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Meta-Analysis Results
The random effects model was selected for calculating standardized mean
differences and 95% CIs since variation was expected to exist among the studies with
dosage amounts, length of treatments, and other variations in the RCTs. Studies that did
not report similar units of 25(OH)D were calculated so all data remained in the same unit
for the meta-analysis. Serum levels of 25(OH)D reported in nmol/L were converted to
ng/ml, using the pertinent conversion factor (1 ng/ml = 2.5 nmol/L) for consistency in the
studies. Three studies (Cooper et al., 2016; Hollis et al., 2011; Roth, Al Mahmud, Raqib,
Akhtar, Perumal et al., 2013) required conversion (Appendix E). Additionally, four
studies had one control group and multiple treatment groups (Hollis et al., 2011; Mir et
al., 2016; Soheilykhan et al., 2013; Wagner et al., 2013). The treatment groups for each
of these studies were pooled and calculated as one treatment as recommended by
Borenstein et al. (2009).
The summary effect size that was calculated for all 19 selected studies used in the
first meta-analysis was large (d = 1.320, SE = .171, 95% CI = .985 – 1.656) (Figure 4.2).
The effect sizes had a wide range of .280 to 5.335. The Q statistic was significant (Q =
274.560, df = 18, p < .001) indicating that heterogeneity existed and a high I2 value of
93.4% was calculated for these studies, which warranted investigation of possible
outliers. Additionally, the forest plot indicated non-overlapping CIs (data not shown) for
the three studies with the largest effect sizes. These were Hashemipouir et al. (2013) (d =
3.811), Roth, Al Mahmud, Raqib, Akhtar, Perumal et al. (2013) (d = 3.726), and
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Karamali, Beihaghi, Mohammadi, & Asemi (2015) (d = 5.335), which are reported in
Figure 4.2 as the standardized difference in the means.
The random effects model uses the treatment effects and variances of the studies
to calculate standardized weighted residuals for each study. The studies were examined
by viewing the standardized residual of each individual study and the impact it had on the
analysis. Large residuals are likely to offset the mean effect and increase the estimate.
According to Viechtbauer and Cheung (2010), the effect sizes in a meta-analysis should
be examined for potential outliers that may influence the study. Examining Figure 4.2
indicated three significant standardized residuals with low p values < .001 from the
studies published by Hashemipouir et al. (2013), Karamali et al. (2015), and Roth, Al
Mahmud, Raqib, Akhtar, Perumal et al. (2013). These were determined to be outliers as
discussed by Hedges and Olkin (1985) and Thomas et al. (2011) and removed from the
meta-analysis. Baker and Jackson (2008) also observed the lowest p values as a guide to
identifying outliers in a meta-analysis.
Removal of the three outlier studies shifted the summary effect size from 1.389 to
.894 (CI = .697 – 1.001, Figure 4.3, Table 4.1), which according to Cohen (1988) is a
large effect. Effect sizes ranged from .280 from the study by Asemi, Samimi, Tabassi,
Shakeri, and Esmaillzadeh (2013) to 1.533 (Sabet, Ghazi, Tohidi, & Oladi, 2012). The
CIs of the 16 studies exhibited overlapping in the forest plot (Figure 4.3). Each study
overlapped with one or more other studies, which indicated the studies in this metaanalysis were comparable (Ried, 2006). In the forest plot (Figure 4.3), the size of the
squares represent the weight assigned to each study based on sample size, which ranged
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from 42 participants in the RCT conducted by Asemi et al. (2016) to 965 participants in
Cooper et al. (2016).
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Figure 4.2 Statistic for Each Study with Standardized Residuals

Figure 4.3
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Statistics for each study

0.297 0.422 1.587
0.303 0.061 1.248
0.317 0.034 1.276
0.286 0.340 1.459
0.290 -0.289 0.848
0.069 0.955 1.226
0.137 0.511 1.047
0.274 0.481 1.557
0.307 -0.069 1.135
0.104 0.396 0.802
0.322 0.902 2.163
0.280 0.630 1.726
0.258 0.842 1.853
0.167 0.207 0.863
0.137 0.427 0.965
0.158 0.685 1.306
0.078 0.697 1.001

Forest Plot of Randomized Controlled Trials

1.005
0.654
0.655
0.899
0.280
1.090
0.779
1.019
0.533
0.599
1.533
1.178
1.348
0.535
0.696
0.996
0.849

Std diff Standard Lower Upper
in means error
limit limit
Asemi 2014
Asemi 2015
Asemi 2016
Asemi Hashemi 2013
Asemi Samimi 2013
Cooper 2016
Hollis 2011
Karamali Asemi 2015
Mir 2016
Mojibain 2015
Sabet 2012
Samimi 2016
Soheilykhan 2012
Vaziri 2016
Wagner 2013
Yap 2014

Study name

-2.50

-1.25

Favors Control

1.25

Favors Intervention

0.00

Std diff in means and 95% CI

Forest Plot of Randomized Controlled Trials

2.50

Table 4.1

Random Effects Estimates and Heterogeneity
Effect size (95% CI lower and upper limit)

Model

Number
of
estimates

Random

16

Point
estimate
(effect
size)
.849

Standard
error

Variance

Lower
limit

Upper
limit

.078

.006

.697

1.001

Test of null
hypothesis
(2- Tailed)
z value p value

10.943

<.001

Heterogeneity
Q value
39.358

df(Q)
15

p value
.001

I2
61.89

Comparing the results of the control and intervention groups indicated vitamin D
supplementation (intervention groups) produced an overall positive effect size favoring
the intervention, which is illustrated at the bottom of the forest plot as a diamond placed
to the right of the 0 (Figure 4.3). It should be noted that two studies had CIs with negative
lower limits (Asemi, Samimi et al., 2013; Mir et al., 2016) and although their effect sizes
were positive, there is the possibility that these two interventions were not effective.
The Cochran’s Q test was significant, which indicated the presence of
heterogeneity (Q = 39.358, df = 15, p = .001, Table 4.1). The significant p value
suggested that more variation existed between the RCTs than expected. The I2 value
quantified heterogeneity as 61.89%, which is considered moderate. The presence of
heterogeneity warranted subgroup analysis to identify possible sources of variation
among the studies.
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Subgroup Analysis
Subgroup analysis was conducted to explore the reasons for heterogeneity.
Moderators for subgroup analysis are presented in Table 4.2. Analysis was conducted
according to the mean age of participants, mean BMI (kg/m2), country (USA/UK/AUS vs
other countries), serum 25(OH)D baseline (<20 ng/mL), pre-existing conditions (preeclampsia or GDM), multivitamin usage, placebo/non-placebo use in the RCT, daily
dosage, high dosage (>30,000 IU), average dosage (< or >2000 IU/d), blinding/nonblinding status, trimester supplementation started (first, second, or third), and
trial/intervention length.
The only moderator that significantly affected between subgroup heterogeneity in
the meta-analysis was the trimester that vitamin D supplementation started (Q = 20.044,
df = 2, p < .001, Table 4.2). The first trimester produced an effect size of 1.091 and the
second and third trimesters’ effect sizes were .699 and .892, respectively. Beginning
supplementation in the first trimester appeared to be more effective. Additionally, the
RCTs that began vitamin D supplementation in the first trimester were similar to each
other and lacked heterogeneity (I2 = 0%); however, there were only three studies included
in the first trimester group. Nine studies began supplementation in the second trimester
and were also similar to each other (I2 = 1.87%), and four studies began supplementation
in the third trimester which had moderate heterogeneity (I2 = 64.88%). Dosage amounts
of vitamin D supplementation that started in the third trimester tended to vary and be at
higher dosages than supplementation initiated in the first and second trimesters.
Although the other moderators did not produce significant Q values for between
subgroup heterogeneity (p > .10), they may be important factors that affect 25(OH)D
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status. A study by Aly et al. (2013) did not report an association between age and BMI
and vitamin D status in pregnant women. The means of the age groups were 22 and 32
years of age, and 22 and 31 kg/m2 BMI in the present study. However, age and BMI can
be factors that affect vitamin D status in different circumstances. Mazahery and von
Hurst (2015) indicated that the response of vitamin D supplementation declines when
BMI is 30 kg/m2 or greater. Although age and BMI are determinant factors in vitamin D
status, lifestyle habits may contribute to the level of 25(OH)D concentration. Kift et al.
(2013) reported that a majority of South Asians were vitamin D insufficient due to
lifestyle habits among other concerns.
Studies grouped according to geographical area did not significantly affect the
heterogeneity among the subgroups (Table 4.2). Twelve studies were conducted in Asia
(Iran, India, Bangladesh) and four were conducted in higher income countries (United
States, United Kingdom, Australia). Babu and Calvo (2010), Ritu and Gupta (2014), and
Sachan et al. (2005) noted that vitamin D deficiency is widespread in India with poor
vitamin D status among mothers and newborns. Therefore, infants breastfed are vitamin
D deficient and are more likely to develop various health conditions. Karras, Anagnostis,
Paschou, Kandaraki, and Goulis (2015) indicated that studies grouped in similar
geophysical regions may eliminate some variation and could provide specific population
recommendations for vitamin D supplementation. However, grouping studies in similar
geographical regions as a moderator was not significant in the present meta-analysis.
Although baseline (pre) levels of 25(OH)D levels less than 20 ng/mL versus
greater than 20 mg/mL as a subgroup did not contribute to between study heterogeneity,
Mazahery and von Hurst (2015) indicated that baseline serum concentration of 25(OH)D
48

contributed to the response of vitamin D supplementation. Yu, Ertl, Samaha, Akolekar,
and Nicolaides (2011) observed that maternal serum 25(OH)D levels at 11 to 13 weeks
gestation was affected by season of the year (higher in summer), age (increased with
age), and decreased with higher BMI levels.
Women with pre-existing conditions of GDM or at risk for pre-eclampsia were
given vitamin D supplementation. Tabesh, Salehi-Abarqouei, Tabesh, and Esmaillzadeh
(2013) reported a relationship existed between vitamin D deficiency and risk of preeclampsia in a systematic review and meta-analysis of observational studies. According
to Kaushal and Magon (2013), these conditions have been linked to vitamin D deficiency.
Adequate vitamin D intake in the prevention of adverse outcomes early in pregnancy may
be beneficial.
Prenatal and multivitamin supplementation are usually recommended during
pregnancy. A multivitamin supplement or multivitamin-mineral supplement was reported
in most of the RCT studies; however, some of the RCTs did not report this information.
Asemi et al. (2014) examined multivitamin and multivitamin–mineral supplementation
usage in pregnancy, the outcomes improved for infants with usage. A RCT by
Taghizadeh et al. (2014) indicated that multivitamin-mineral supplementation had
beneficial effects compared to multivitamin supplementation for 20 weeks during
pregnancy. The use of multivitamins varies and is related to income, health insurance
status, age, race/ethnicity, education, and marital status according to Branum, Bailey, and
Singer (2013) and Sullivan, Ford, Azrak, and Mokdad (2009).
The between subgroup effect of using a placebo (control) to RCTs not using a
placebo from various weeks of gestation to delivery was not significant in contributing to
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the heterogeneity of the meta-analysis (p = .538, Table 4.2). Hrobjartsson and Gotzche
(2010) reported that although claims of improvement with placebo gave favorable results,
most studies were not based on randomized patients.
Dosage amounts of vitamin D varied in the RCTs. Vitamin D supplements given
daily (p = .870), given in an average amount of 2000 IU/d or greater (p = .301), or in a
large bolus (30,000 IU or greater) (p = .215) were not significant in contributing to
heterogeneity between the subgroups (Table 4.2). Dosage appears to be important in how
deficient the individual is and how much vitamin D may be needed to reach a level of
sufficiency. Moon et al. (2016) suggested that several determinants may affect the
response of vitamin D supplementation in achieving sufficiency in vitamin D with
various dosages. Various factors may contribute to deficiency and insufficiency among
the population of pregnant women. Saadi et al. (2007) reported that lactating and
nulliparous women taking vitamin D2 supplementation of 2000 IU/d or 60000 IU/month
increased serum vitamin D concentrations. Monthly intake of vitamin D2 was safe and an
effective alternative to daily dosing. De-Regil, Palacios, Lombardo, and Peña-Rosas
(2016) reported in several trials where vitamin D supplements were given on a daily basis
and serum 25(OH)D status was higher than those receiving the placebo.
Whether the RCT was a blinded or a non-blinded study did not significantly affect
between subgroup heterogeneity (Table 4.2). Thirteen studies were double- or singleblinded and three were not blinded. According to Day and Altman (2000), blinding varies
according to circumstances, or with different outcome events (Veerus, Fischer, Hakama,
Hemminki, & The EPHT Trial (2012) and not always easy or possible. Blinding among
RCTs often does not specify which groups are actually blinded. A priori consideration of
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groups involved in clinical studies need to be blinded but open-label or non-blinded
clinical trials designs are sometimes unavoidable (Miller & Stewart, 2010). Blinding of
participants in RCTs is important particularly when of a subjective nature. It leads to less
risk of bias among the study. Double-blinded studies involve blinding of both the
participants and the researchers interacting with the participants, and has less risk for
performance bias and detection bias than single-blinded trials. Single-blinded trials
involve either the participant or the researcher being unaware which treatment the
participant is receiving. Day and Altman (2000) reported a larger treatment effect may be
observed for non-blinded studies. According to Karanicolas, Farrokhyar, and Bhandari,
(2010), blinding in RCTs is common practice to minimize differences between groups
but differential treatment of participants may occur and result in bias. Hrobjartsson et al.,
(2013) reported that RCTs with blinded or non-blinded accessors observed more bias by
the non-blinded assessors, exaggerating the effect size. A study of 12 blinded or nonblinded RCTs resulted in bias with non-blinded patients in patient-reported outcomes
(Hróbjartsson, Emanuelsson, Skou Thomsen, Hilden, & Brorson, 2014). Another study of
blinded and non-blinded participants in a hormone therapy trial indicated that the effect
of blinding varied for different outcomes (Veerus et al., 2011).
Subgroup analysis of the trimester when vitamin D supplementation began
significantly affected the heterogeneity of the meta-analysis (p < .001, Table 4.2).
Vitamin D status improved especially when the supplementation began in the first
semester. Seda et al. (2016), Fernandez-Alonso et al. (2012) and Schneuer et al. (2014)
proposed that vitamin D status in the first trimester had no association with increased
positive pregnancy outcomes. A systematic review by Nassar, Halligan, Roberts, Morris,
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and Ashton (2010) reported no association of low vitamin D levels in early pregnancy
(first trimester) to adverse pregnancy outcomes, although most women in the combined
studies were vitamin D deficient. The deficiency may have been related to clothing
customs such as women who remain covered when outdoors, season of sampling, or use
of multivitamins. Xiang et al. (2013) reported that vitamin D concentrations for pregnant
women working in urban areas and indoors in China were lower in the second trimester
than in the third trimester which varied according to season. Also, third trimester low
levels may be attributed to the need for increased calcium and multivitamin
supplementation (Xiang et al., 2013).
Latitude of the country and season of the year as possible subgroups that
influence vitamin D status were not feasible in this meta-analysis. Although most of the
studies occurred at a latitude less than 37°, the lifestyle and behavioral factors of the
general population may have a bearing on the effect of vitamin D status. Season of the
year of delivery was not clearly stated in all studies with a range from trimester to
delivery posing a problem in reporting it accurately as a subgroup.
Davies-Tuck et al. (2015) reported pregnant women tested in winter or spring
were 50% more likely to be deficient than women in summer. Seasonal change in
25(OH)D3 related to change in vitamin D status was affected by geographical origin,
clothing style, sun exposure behavior, vitamin D supplementation, and dietary intake in
the third trimester and travel in areas less than 35° latitude in the last few months of
pregnancy (Barebring et al. 2016). This study included a multi-ethnic group of pregnant
women from Africa and Asia observed in early and late pregnancy from January to
December (Barebring et al. 2016).
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Table 4.2

Results of the Summary Effect Sizes for the Subgroup Moderators

Age (years)
<27
≥27
BMI (kg/m2)
<25
>25
Country
Other
USA/UK/AUS
25(OH)D Baseline
(<20ng/mL)
No
Yes
Pre-existing condition
No
Yes
Multivitamin Usage
No/Not reported
Yes
Placebo used
No
Yes
Daily dosage
No
Yes
High Dosage
(>30000 IU)
No
Yes
Average Dosage
<=2000IU/d
>2000 IU/d
Blinded study
No
Yes
Trimester started
First
Second
Third
Trial Length
≤9 weeks
>9weeks

k
(number of
studies)

Effect size
(95% CI)

Standard
error

Q value
(df)

I2
(%)

6
10

0.820 (0.441 - 1.199)
0.867 (0.705 - 1.029 )

0.193
0.083

0.050(1)

68.23
59.33

3
13

0.832 (0.241 - 1.423)
0.862 (0.705 - 1.019)

0.302
0.080

0.010(1)

74.88
59.38

12
4

0.823 (0.622 - 1.023)
0.907 (0.702 - 1.112)

0.102
0.105

0.331(1)

51.50
66.75

6
10

0.858 (0.659 - 1.056)
0.836 (0.615 - 1.057)

0.101
0.113

0.020(1)

37.08
70.90

11
5

0.823 (0.624 - 1.022)
0.944 (0.735 - 1.154)

0.102
0.107

0.679(1)

73.53
0

7
9

0.896 (0.567 - 1.226)
0.827 (0.650 - 1.003)

0.168
0.090

0.133(1)

55.89
68.88

6
10

0.794 (0.605 - 0.983)
0.885 (0.667 - 1.104)

0.096
0.112

0.380(1)

30.08
70.90

11
5

0.865 (0.644 - 1.086)
0.839 (0.621 - 1.056)

0.113
0.111

0.027(1)

52.03
73.81

8
8

0.767 (0.568 - 0.967)
0.979 (0.710 - 1.248)

0.102
0.137

1.536(1)

67.52
59.13

5
11

0.685 (0.323 - 1.046)
0.895 (0.728 - 1.063)

0.185
0.085

1.071(1)

77.06
48.13

3
13

0.810 (0.331 - 1.289)
0.865 (0.707 - 1.024)

0.244
0.081

0.046(1)

73.47
54.47

3
9
4

1.091 (0.970 - 1.211)
0.699 (0.577 - 0.821)
0.892 (0.463 - 1.320)

0.061
0.062
0.219

20.044(2)*

0
1.87
64.88

8
8

0.888 (0.660 - 1116)
0.827 (0.617 - 1.037)

0.116
0.107

0.149(1)

32.50
75.80

Note. Significance for Q value indicating heterogeneity is the between subgroup effects
*p < .001, I2 values are within subgroup effects.
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Table 4.3

Possible Moderators that could not be analyzed due to Missing Data

Moderators not used in the
meta-analysis due to missing
data
Race/ethnicity
(> 90% of one race/ethnicity)
Education level

Number of studies (references)
reporting sufficient data (N = 16)

Dietary intake information

5 (All <RDA, unable to analyze.
Asemi, Hashemi et al., 2013;
Asemi & Karamali, 2014; Hollis
et al., 2011; Karamili, Asemi et
al., 2015, ; Samimi et al., 2015)
1 (Vaziri et al., 2016)

Sun exposure

2 (Cooper et al., 2016; Wagner
et al., 2013)
2 (Hollis et al., 2011; Vaziri et
al., 2016)

Season at study entry

2 (Cooper et al., 2016; Vaziri et
al., 2016)

Employment status
Medical insurance

2 (Hollis et al., 2011;Vaziri et
al., 2016)
1 (Hollis et al., 2011)

Smoking status

1 (Cooper et al., 2016)

Planned pregnancy

3 (Hollis et al., 2011; Vaziri et
al., 2016; Wagner et al., 2013)
1 (Cooper et al., 2016)

Physical activity/exercise
Clothing/traditional dress such
as veiled women

0 studies

Comments
Insufficient data or not
mentioned in other studies
Insufficient data (Cooper et al.,
2016; Mojibian et al., 2015),
not mentioned in other studies
Insufficient data (Asemi &
Esmailzadeh, 2015; Asemi,
Samimi et al., 2013), not
mentioned in other studies
Insufficient data or not
mentioned in other studies
Insufficient data (Hollis et al.,
2011; Mir et al., 2016;
Mojibian et al., 2015) not
mentioned in other studies
Insufficient data or not
mentioned in other studies
Insufficient data or not
mentioned in other studies
Insufficient data or not
mentioned in other studies
Insufficient data or not
mentioned in other studies
Insufficient data or not
mentioned in other studies
Insufficient data (Sabet et al.,
2012), not mentioned in other
studies

A study by Mirsaeid Ghazi, Rais Zadeh, Pezeshk, and Azizi (2004) attributed
vitamin D deficiency to lifestyle and traditional clothing of the women in Tehran. There
were no difference in vitamin D status in three seasons; however, winter showed a
significant change in vitamin D status (Mirsaeid Ghazi et al., 2004). Mazahery and von
Hurst (2015) reported various factors that affected serum 25(OH)D levels in response to
supplementation, which included environment, treatment strategy, individual
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characteristics, and biological factors. The lifestyle and nutritional status among mothers
in Turkey noted that although sunny conditions existed, vitamin D deficiency and
insufficiency were highly prevalent (Haliciogue et al., 2011). Lips, van Schoor, and de
Jongh (2014) reported that diet, exposure to sun, and lifestyle affect vitamin D status and
a combination of nutrition, sun exposure, food fortification and supplementation provide
the best results in being sufficient across all seasons. The season of the year as a potential
modifier was not reported in all studies or may have covered all seasons in the duration of
the ongoing studies with no defined season of delivery. Additionally, missing data from
the RCTs did not allow for race or ethnicity as a potential moderator; other possible
moderators that could not be used due to missing data are presented in Table 4.3.
A meta-analysis by Palacios, De-Regil, Lombardo, and Pena-Rosas (2016)
reported RCTs of vitamin D supplementation during pregnancy of women with varied
health conditions. They reported high heterogeneity (I2 = 99%) which led to inconsistent
results of higher levels of 25(OH)D compared to placebo/control. The high degree of
heterogeneity in Palacios et al. (2016) may be explained by variation in study design,
varying dosages of vitamin D supplementation, duration of the study, and discrepancies
in participant’s conditions. Perez-Lopez et al. (2015) also reported an extremely high I2
value of 100% in 10 RCTs that observed an outcome of higher 25(OH)D levels in
pregnant women with vitamin D supplementation; the high heterogeneity may be from
what appears to be an outlier illustrated on their forest plot.
Yang et al. (2015) reported a high I2 value of 98.8% in 14 RCTs and attributed it
to supplementation regimens and different control groups used in the RCTs; however,
there appears to be an outlier in their forest plot results. The overall results showed an
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improved cord blood 25(OH)D concentration in women with low 25(OH)D status (Yang
et al., 2015). A meta-analysis of 32 RCTs with 42 intervention-control comparisons by
Roth et al. (2017) observed an increase in maternal/cord serum concentrations of
25(OH)D with a weak dose-response effect. Their results showed that prenatal vitamin D
supplementation had positive outcomes such as increased birth weight and reduced the
risk of wheezing (asthma) in the women’s children. They reported an I2 value of 96%
which was not addressed (Roth et al., 2017). Eighty to 90% of pregnant women given
high doses of vitamin D (> 3000 IU/day) reached a 25(OH)D level of 20 ng/mL or higher
in a meta-analysis using RCTs by Chakhtoura et al. (2017). They did not report an overall
I2 value; however, subgroup analysis showed high heterogeneity (I2 = 95%) in five RCTs
of pregnant women given greater than 2000 IU/day versus less than 800 IU/day of
vitamin D (Chakhtoura et al., 2017). Although previous meta-analyses reported valuable
information about the importance of vitamin D in pregnancy, the current meta-analysis
was cognizant of meta-analytic procedures such as identifying outliers and addressing
heterogeneity. Ried (2006) states that heterogeneity indicates the comparability of the
studies used in a meta-analysis. Israel and Richter (2011) reported that “high
heterogeneity may indicate that it is inappropriate to combine studies in a meta-analysis”
(p. 500).

Publication Bias
Publication bias can occur in a meta-analysis and can be visually inspected from a
funnel plot. The funnel plot appears to be symmetrical (Figure 4.4) and therefore
publication bias was not detected. The 16 studies included in the meta-analysis are shown
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as the small hollow circles on the plot and the hollow diamond on the bottom of the plot
gives the overall effect of the studies. The imputed dark diamond below the hollow
diamond is symmetrically positioned under the hollow diamond which indicates a lack of
publication bias. Asymmetry of plotted treatment effects of studies against its standard
error would indicate publication bias. A horizontal scattering of studies (hollow circles)
with gaps in the funnel would cause the plot to be asymmetrical and indicate publication
bias. The detection of asymmetry in a funnel plot shows the tendency for smaller studies
to be further away from the null than the larger studies (Sterne, Sutton, Loannidis, Terrin,
& Jones, 2000).
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Figure 4.4

Funnel Plot of Standardized Error of Randomized Controlled Trials
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Publication bias can also be assessed by Classic fail safe N and Duval and
Tweedie’s trim and fill test methods. These methods estimate if studies are missing with
smaller effect sizes that should be included in the analysis, and therefore the p value for
the summary effect would not be significant. If there are actually a small number of
missing studies, it could affect the overall results of the meta-analysis. A reported large
number of missing studies would not be a concern. These studies are incorporated in the
analysis before the p value becomes nonsignificant (Higgins et al., 2011). Results for
classic fail safe N for publication bias indicated that 1380 missing studies would bring the
p value to greater than alpha (Table 4.4). It is highly unlikely that 1380 studies could be
located to include in this meta-analysis. It was suggested by Rosenthal (1991) that a fail
safe N greater than 5k + 10 (k is the number of studies included in the meta-analysis)
would indicate a robust effect. The fail safe N of 1380 reported in Table 4.3 far exceeds
90 (5(16) + 10 = 90) in the present meta-analysis, which indicated a low level of
publication bias.

Table 4.4

Classic Fail Safe N for Publication Bias and Estimation for Number of
Missing Studies
z value for observed studies
p value for observed studies

18.303
<.0001

Alpha
Tails
Z for alpha

.050
2
1.96
16
1380

Number of observed studies

Number of missing studies that would bring p value to > alpha
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Duval and Tweedie’s Trim and Fill
The Duval and Tweedie’s trim and fill approach to publication bias observes
studies that may be more to the left or right of the summary effect size. If publication bias
is thought to occur, Duval and Tweedie’s trim and fill test will remove small studies from
the positive side of the funnel plot and assess the effect size by making the funnel plot
symmetrical with the different effect sizes (Higgins et al, 2011). Figure 4.4 displays the
funnel plot which includes observed estimates in the meta-analysis (hollow circles).
There were no imputed estimates, which would occur as dark circles on the plot;
therefore, publication bias was not detected with the studies found for this meta-analysis.
Duval and Tweedie’s trim and fill indicated there was a balanced funnel plot and it
achieved symmetry. The observed pooled estimate (effect size) is shown as the hollow
diamond and was symmetrical with the imputed dark diamond. The effect size (point
estimate) was .849 and observed values and adjusted values were the same (Table 4.5),
which further indicated that publication bias was not detected in this study.

Table 4.5

Observed
values
Adjusted
values

Duval and Tweedie’s Trim and Fill Analysis for Publication Bias
Random Effects
Studies
Point
Trimmed
Estimate
0.849
0

0.849
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Lower
Limit
0.697

Upper
Limit
1.001

0.697

1.001

Q value
39.358
39.358

CHAPTER V

CONCLUSION
The prevalence of vitamin D deficiency is common in all groups of individuals
and affects health beyond its traditional influence on skeletal health. It has been known to
affect the outcomes for both mother and infant in various ethnic populations and at
different latitudes. This systematic review and meta-analysis provided an overview of the
existing literature of RCTs which evaluated the effectiveness of interventions to increase
serum 25(OH)D concentrations of women during pregnancy. The use of RCTs for
assessing the effectiveness of interventions is considered the gold standard in research
(Panesar, Thakrar, Athanasiou, & Sheikh, 2006). Combining RCTs into a meta-analysis
study is a useful tool for evaluating clinical studies.
This meta-analysis of RCTs indicated that interventions of vitamin D
supplementation of various dosages improved vitamin D status compared to those with
no supplementation in pregnant women with and without pre-existing conditions. The
overall effect size was large (d = .849), which demonstrated that vitamin D
supplementation was effective in increasing vitamin D status among pregnant women. It
was observed that many groups of pregnant women had mean serum 25(OH)D
concentrations well below the sufficient range and that interventions were beneficial.
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Various complications in pregnancy are thought to be affected by insufficient
vitamin D status such as pre-eclampsia, caesarean section, and gestational diabetes
(Kaushal & Magon, 2013; Lin et al., 2011; Robinson et al., 2010). Maternal vitamin D
concentrations at delivery showed favorable results in many outcomes when women were
supplemented with vitamin D. Recommendations for vitamin D intakes during pregnancy
have not been consistent; however, results are evident in routine vitamin D
supplementation for improving pregnancy outcomes. Studies of meta-analyses showed
that vitamin D supplementation during pregnancy on maternal outcomes indicated
25(OH)D levels were higher compared to the placebo/control with inconsistent results in
some of the maternal outcomes for mother and baby (Palacios et al., 2016; De-Regil et
al., 2016; Wei, Qi, Luo, & Fraser, 2013). Characteristics varied among populations such
as diet and sun exposure with some studies reporting variations; however, some studies
did not provide information about factors that could affect intervention outcomes.
Meta-analyses often encounter heterogeneity which was observed in this study.
Sources of heterogeneity were investigated by subgroup analysis. Subgroup analysis was
performed for a variety of possible characteristics that could cause variation among the
studies. Among various subgroups analyzed, the trimester when vitamin D
supplementation was started only showed significance for affecting overall heterogeneity
of the meta-analysis. Starting vitamin D supplementation in the first trimester was more
effective than beginning in the second or third trimester. Other subgroup moderators were
not significant in affecting heterogeneity. Although most RCTs are blinded, this study did
not see a difference affecting heterogeneity in blinded or non-blinded studies. Miller and
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Stewart (2011) suggested a misuse of blinding in RCTs in terms of how single, double,
and triple blinded are defined.
Publication bias has been observed in meta-analyses and may affect the overall
results. This meta-analysis did not detect publication bias using visual inspection of the
funnel plot in addition to Classic fail safe N and Duval and Tweedie’s trim and fill test
methods. With the absence of publication bias, this meta-analysis was considered valid
(Borenstein et al., 2009). Overall, the meta-analysis showed the interventions were
significantly effective at increasing the serum 25(OH)D concentrations among pregnant
women. However, as with all meta-analyses, the conclusions that can be drawn are
dependent on the studies used in the analysis.
Despite inconclusive evidence of vitamin D supplementation during pregnancy to
correct for various adverse outcomes, the need for, and benefits of vitamin D
supplementation in pregnancy is supported by RCTs. The interventions were beneficial in
ensuring pregnant women received adequate amounts of vitamin D supplementation to
promote optimal health. Women supplemented with vitamin D during pregnancy
compared with those with no supplementation had higher 25(OH)D levels. Various large
dosages at or exceeding 30,000 IU in a nondaily bolus in several studies did not report
any adverse effects. Routine testing for vitamin D status could be beneficial, especially in
pregnant women. Although the cost of testing for vitamin D status can be prohibitive, it
may be applicable during pregnancy where the cost of testing may outweigh preventable
adverse outcomes. Holick (2007) stated that because of the high cost of testing for serum
concentrations of 25(OH)D and the high prevalence of vitamin D deficiency, routine
vitamin D supplementation would be beneficial.
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51
September November
2013
(6 weeks)

Study Characteristics of Included Studies
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2014

Table B.1

85
31.8 ±6.6
31.7 ±5.6

24.3 ±3.4
25.7 ±4.2

24.4 ±3.6
25.0 ±4.2

30.8 ±6.6

Mean age

(2 times; baseline &
day 21)

-Placebo
-50000 IU

-Placebo
-200 IU + Ca

(multivitamin)

-Placebo
-400 IU/d

-Placebo
-50,000 IU (twice)
+ calcium

Intervention
(IU)

24-26 wks gestation
20.41 ±13.43
20.44 ±14.31

25 wks gestation
13.8 ±6.9
12.1 ±6.1

25 wks gestation
15.58 ±6.53
18.25 ±6.74

Mean pre
(baseline/pre)
ng/mL
24-28 wks gestation
19.62 ±13.72
20.32 ±14.19

20.92 ±13.79
38.95 ±24.72

11.1 ±5.1
13.6 ±6.0

14.21 ±6.21
22.04 ±9.26

17.24 ±11.27
36.5 ±21.84

Mean -post
(delivery)
ng/mL

Supplementation
resulted in increase in
serum vitamin D
concentration
compared to placebo

Vitamin D
multivitamin
supplementation
resulted in increased
serum minerals and
vitamin D levels
Vitamin D levels
improved maternal
status

Supplementation
resulted in increasing
serum 25(OH)D
concentrations

Main outcome

United
Kingdom
(Southhampton,
Oxford,
Sheffield)
Iran

Cooper 2016

USA
(South Carolina)

Iran

Iran

India

Hollis 2011

Karamali 2015

Karamali 2016

Mir 2016

Hashemipour
2013

Iran

(continued)

Asemi, Samimi
2013

Table B.1
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RCT
Open-label
parallel
group

RCT,
Doubleblinded

RCT
Doubleblinded

RCT
Single
center;
Doubleblinded

RCT
Open label

RCT
Doubleblinded

RCT

87

60

60

350

109

965

48

May - July

March July 2014

July 2014 Oct, 2014
(12 weeks)

Jan 2004 July 2009
(66 months)

June 2008 Nov 2014
(20 weeks;
72 months
overall)
December
2011 March 2012
(3 months)

March 2012
- September
2012

28.0 ±6.4
24.5 ±7.0
26.3 ±5.3
27.3 ±5.6

31.6 ±6.3
28.7 ±6.1

27.4 ±5.2
(mean age)

27.4 ±5.7
26.6 ±5.4

27.0 ±5.6

25.05 ±4.62

27.62 ±4.63

30.5 ±5.2

30.5 ±5.2

24.8 ±3.6
25.3 ±4.2

-1000 IU/d
-30000 IU/month
-2000 IU/d
-60000 IU/month

Placebo
50000 IU (plus
Ca)

Placebo
50000 IU/every 2
wks

-400 IU/d
(Placebo)
-2000 IU/d
-4000 IU/d

-Control
(multivitamin)
-50,000 IU/wk
(7142 IU/d)

-Placebo
(multivitamin)
-1000 IU/d

-Placebo
-400 IU/day

16 wks gestation
26.5 ±16.0
26.0 ±17.1
22.6 ±13.0
21.6 ±13.8

24-28 wks gestation
20.8 ±14.4
21.3 ±14.4

17.10 ±2.21
17.37 ±4.04

20-32 wks gestation

37.7 ±11.3
41.2 ±12.6
36.1 ± 9.9
44.7 ±13.1

17.3 ±10.9
36.3 ±21.3

16.99 ±1.40
34.91 ±2.36

31.56 ±14.6
39.32 ±13.68
44.4 ±16.16

47.8 ±11.1

15.8 ±5.6
12-16 wks gestation
24.64 ±27.1
23.32 ±8.92
23.28 ±8.72

15.9 ± 6.6

27.28 ±8.76

17.32 ±8.92

13.3 ±1.1
21.5 ±24.72

26-28 wks gestation
17.5 ±4.8

18.68 ±7.08

14 wks gestation
18.36 ±6.8

25 wks gestation
14.5 ±1.2
17.8 ±1.3

Significant increase
in serum 25(OH)D
concentration with
supplements
compared to placebo
Vitamin D
supplementation had
significantly
increased serum
25(OH)D
concentrations
Vitamin D
supplementation of
2000 IU/day or 60000
IU/month is effective

4000 IU most
effective in achieving
vitamin D sufficiency

Vitamin D levels
improved maternal
status

Significant increase
in serum 25(OH)D
concentrations and
beneficial on
metabolic status
Improved vitamin D
status

Iran

Bangladesh

Iran

Iran

Iran

Iran

USA
(South
Carolina)

Australia

Roth 2013

Sabet, 2012

Samimi 2016

Soheilykhah
2013

Vaziri 2016

Wagner 2013

Yap 2014

(continued)

Mojibian
2015
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RCT
Doubleblinded

(NICHD study)

RCT
Doubleblinded

RCT

RCT
Not blinded

RCT
Double blinded

RCT

RCT

RCT
Not blinded

179

341

130

75

60

50

130

389

Feb 2010 Nov 2011

Nov 2006 June 2010
(43 months)

Nov 2014 Oct 2015

September
2014February
2015
2009 - 2011

Aug 2010 Jan 2011
3rd trimester
2009 - 2010

2010 - 2012

28.8 ±4.9
29.5 ±4.7

27.0 ±5.1
26.0 ±5.3
26.0 ±5.0

26.22 ±4.33
26.40 ±4.88

400 IU/d (control)
5000 IU/d

-400 (control)
-2000 IU/d
-4000 IU/d

-Control
-2000 IU/d

-200 (control)
-50000 IU/month
-50000 IU every 2
wk

-Placebo
-50,000 IU every 2
wks

27.1 ±5.2
27.3 ±3.7
25.0 ±4.3
26.5 ±4.5
26.3 ±4.8

-Placebo
-100,000 IU/
month (3 times)

-Placebo
-35000 IU/wk

-400
-50000 IU every 2
wks

26.0 ±6.2
26.6 ±4.7

27.3 ±4.9
27.8 ±5.0

18.0 ±7.0
20.0 ±7.0

14 wks gestation

24.6 ±10.9
23.2 ±8.6
22.8 ±9.7

12– 16 wks gestation

26-28 wks gestation
11.89 ±6.40
12.84 ±7.91

12 wks gestation
8.3 ±7.8
7.3 ±3.8
7.3 ±5.9

20 wks gestation
16.2 ±3.5
13.1 ±6.4

28 wks gestation
38.3 ±23.2
33.5 ±21.4

26-30 wks gestation
44.0 ±20.9

12 wks gestation
15.31 ±5.19
14.46 ±5.19

24 ±9.0
36 ±11.0

30.7 ±14.1
37.1 ±14.7
41.9 ±16.2

12.07 ±5.98
17.46 ±10.09

17.7 ±9.3
27.2 ±10.7
34.1 ±11.5

16.3 ±4.9
21.3 ±8.4

29.4 ±16.0
61.45 ±30.0

38.4 ±18.1

27.2 ±18.8
37.9 ±19.8

Vitamin D
supplementation at
5000 IU/d is safe;
Supplementation for
blood glucose levels
not effective

Lower risk of
hypovitaminosis D
with 4000 IU/day

Vitamin D levels
raised above
50nmol/L
100,000 IU monthly
is safe for pregnant
women; increase in
vitamin D level
After 12 wks serum
25(OH) conc inc with
vitamin D plus
calcium
Supplementation of
pregnant women with
50 000 IU vitamin D
every 2 weeks
improved insulin
resistance
Decreased prenatal
depression

50000IU raised
vitamin D levels at
the time of delivery

APPENDIX C
DATA EXTRACTION FOR STUDIES
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Table C.1

Data Extraction for Asemi & Karamali 2014

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-Total completed
Intervention
Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Pre/Post Data

Baseline data (ng/mL)

Post data (ng/mL)
Overall Study
Evaluation outcome

Christine Rogers
Diane Tidwell
Effects of calcium-vitamin D co-supplementation on glycaemic control,
inflammation and oxidative stress in gestational diabetes: A randomized
placebo-control trial
Asemi & Karamali, 2014
Location in text
(pg/fig/table)
All study participants (researcher and participants) blinded 1799
56
Abstract
51
-Placebo
Abstract
-50,000 IU (twice) and 1,000 mg calcium/d
(6 weeks)
Women diagnosed with GDM
1799
Iranian
Kashan, Iran
Abstract
Women attending maternity clinics affiliated to Kashan
1799
University of Medical Science screened for GDM
Assess the effect of calcium and vitamin D
Abstract
supplementation on metabolic status of pregnant women
with GDM
September 2013 (24-28 weeks gestation)
1799; Methods
November 2013
1799; Methods
Placebo
Calcium & Vitamin D
Table 1
30.8 ±6.6
28.7 ±6.0
30.5 ±4.6
29.4 ±4.6
Low/high/unclear
Support for judgement
1799/Abstract
Low
All study participants (researcher and
participants) blinded; randomization by
computer-generated random numbers
Placebo
Mean

SD

19.62

13.72

50,000 IU
Number of
participants
28

Placebo
Mean
SD
Number of
participants
20.32
14.19
25
X Positive
____ Negative

Mean

SD

17.24

11.27

Number of
participants
28

50,000 IU
Mean

SD

36.52

21.84

Number of
participants
26

Supplementation resulted in increased serum 25(OH)D concentrations;
supplementation has beneficial effects on metabolic profile
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Table C.2

Data Extraction for Asemi & Esmaillzadeh 2015

Data extracted by:
Data checked by:
Reference
Author(s)
Study
Characteristics
RCT design/notes
Participants
-total completed
Intervention

Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias
Pre/Post Data

Baseline data (ng/mL)

Christine Rogers
Diane Tidwell
The Effect of multi mineral-vitamin D supplementation on pregnancy
outcomes in pregnant women at risk for pre-eclampsia
Asemi & Esmaillzadeh, 2015
Location in text
(pg/fig/table)
Double-blinded
Abstract
52
abstract
46
Fig 1
-Placebo
Abstract
-Multi mineral-vitamin D supplements containing 800
mg calcium, 200 mg magnesium, 8 mg zinc, and 400
IU vitamin D
(9 weeks)
Participants at risk for pre-eclampsia
Abstract
Iranian
Kashan, Iran
Methods
Women that attended maternity clinics affiliated to
Methods
Kashan University of Medical Sciences, Kashan, Iran
To determine the favorable effects of multi mineralAbstract
vitamin D supplementation on pregnancy outcomes
among women at risk for pre-eclampsia.
November 2013 (27 week gestation)
Methods
May 2014 (36 week gestation)
Methods
Placebo
Multi mineral-vitamin D supplements Table 1
24.4 ±3.6
25.0 ±4.2
25.5 ±3.7
25.4 ±3.7
Low/high/unclear
Support for judgement
Low
Computer generate random numbers enrolled by trained
midwife
Placebo
Mean

SD

15.58

6.53

400 IU (multi-mineral)
Number of
participants
23

Mean

SD

18.25

6.74

Placebo

Post data (ng/mL)

Mean

SD

14.21

6.21

Number of
participants
23

400 IU (multi-mineral)
Number of
participants
23

Mean

SD

22.04

9.26

Number of
participants
23

Overall Study

X Positive
_____Negative

Evaluation outcome

Multi-mineral vitamin D supplementation increased circulating levels of
vitamin D, serum calcium, magnesium and zinc
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Table C.3

Data Extraction for Asemi & Samimi 2016

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-Total completed
Intervention
Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Christine Rogers
Diane Tidwell
Calcium-vitamin D co-supplementation affects metabolic profiles, but not
pregnancy outcomes, in healthy pregnant women.
Asemi & Samimi, 2016
Location in text
(pg/fig/table)
Double-blinded
46
Fig 1
42
Abstract
-500 mg calcium + 200 IU cholecalciferol supplements
Abstract
-placebo
(9 weeks)
Healthy women with no pre-eclampsia, GDM or placenta Methods
abruption
Iranians
Kashan, Iran
Methods
Attended the maternity clinics in Kashan
Methods
Evaluate the effects of calcium plus Vitamin D
administration on metabolic status and pregnancy
outcomes in healthy pregnant women
March 2012 (25 weeks gestation)
Methods
September 2012
Methods
Placebo
200 IU
Table 1
24.3 ±3.4
25.7 ±4.2
27.0 ±3.8
27.9 ±3.8
Low/high/unclear
Support for judgement
Low
Randomly allocated

Pre/Post Data

Baseline data (ng/mL)

Placebo
Mean

SD

13.8

6.9

200 IU
Number of
participants
21

Mean

SD

11.1

5.1

Placebo
Mean
Post data (ng/mL)
Overall Study
Evaluation outcome

SD

Number of
participants
21

200 IU
Number of
participants
21

Mean

SD

12.1
6.8
13.6
__X_Positive
____Negative
Vitamin D levels improved maternal status

6.0
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Number of
participants
21

Table C.4

Data Extraction for Asemi & Hashemi 2013

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Study Notes
Population description
Location
Method of recruitment
Aim of study

Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias
Pre/Post Data

Baseline data (ng/mL)

Christine Rogers
Diane Tidwell
Effect of vitamin D supplementation on glucose metabolism, lipid
concentration, inflammation, and oxidative stress in gestational diabetes: A
double-blind randomized controlled clinical trial
Asemi & Hashemi 2013
Location in text
(pg/fig/table)
Double-blinded
Abstract
54
Abstract
54
Fig 1
-Placebo (2 times, baseline and 21 days)
Abstract
-50,000 IU (2 times, baseline and 21 days)
(6 weeks)
Study design
Pregnant women with GDM
Abstract
Iranian
Kashan, Iran
Subject/Method
Pregnant women aged 18–40 y diagnosed with GDM by
a 100-g oral-glucose-tolerance test (OGTT) at 24–28 wk
gestation
To assess the effects of vitamin D supplementation on
Abstract
metabolic profiles, high-sensitivity C-reactive protein,
and biomarkers of oxidative stress in pregnant women
with GDM
January 2013
Subject/Method
April 2013
Subject/Method
Placebo
50,000IU
31.8 ±6.1
31.7 ±5.6
Table 1
30.7 ±6.6
30.9 ±4.5
Low/high/unclear
Support for judgement
Low
RCT, double-blinded; subjects were randomly
assigned
Placebo
Mean

SD

20.41

13.43

50,000 IU
Number of
participants
27

Mean

SD

20.44

14.31

Placebo
Mean
Post data (ng/mL)
Overall Study
Evaluation outcome

SD

20.92
13.79
X Positive
____Negative

Number of
participants
27

50,000 IU
Numbers of
participants
27

Mean

SD

38.95

24.72

Number of
participants
27

Supplementation increased serum 25(OH)D concentrations;
supplementation has beneficial effects on glycemic and total /LDL cholesterol
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Table C.5

Data Extraction for Asemi & Samimi 2013

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Study Notes
Population description
Location
Method of recruitment
Aim of study

Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Pre/Post Data

Baseline data (ng/mL)

Christine Rogers
Diane Tidwell
Vitamin D supplementation affects serum high-sensitivity C-reactive protein,
insulin resistance, and biomarkers of oxidative stress in pregnant women
Asemi & Samimi 2013
Location in text
(pg/fig/table)
Double-blinded
Abstract
54
Abstract
48
1433, Fig 1
-Placebo
Abstract
-400 IU/d
(9 weeks)
Healthy pregnant women
Abstract
Iranian
Kashan, Iran
1433
Attended maternity clinics affiliated with Kashan
1433
University of Medical Sciences, Kashan, Iran
To determine the effects of vitamin D supplementation
Abstract
on serum concentrations of high-sensitivity C-reactive
1434
protein (hs-CRP), metabolic profiles, and biomarkers of
oxidative stress in healthy pregnant women.
Increase in serum 25(OH)D
March 2012
1433
September 2012
1433
Placebo
400 IU
1434, Table 1
24.8 ±3.6
25.3 ±4.2
27.4 ±4.0
26.8 ±3.9
Low/high/unclear
Support for judgement
Low
RCT, double-blind
Random assignment was performed by the use of
computer-generated random numbers; trained midwife
performed the randomized allocation sequence and
assigned participants to the groups
Placebo
Mean

SD

14.5

1.2

400 IU
Number of
participants
24

Mean

SD

13.3

1.1

Placebo
Mean
Post data (ng/mL)
Overall Study
Evaluation outcome

SD

17.8
1.3
X Positive
Negative

Number of
participants
24

400 IU
Number of
participants
24

Mean

SD

21.5

24.72

Number of
participants
24

Supplementation has significant increase in serum 25(OH)D concentration
and calcium; supplementation has beneficial effects on metabolic status.
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Table C.6

Data Extraction for Cooper 2016

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Study Notes
Population description
Location
Method of recruitment

Aim of study

Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Christine Rogers
Diane Tidwell
Maternal gestational vitamin D supplementation and offspring bone health:
A multicentre randomised, double-blind, placebo-controlled trial
(MAVIDOS)
Cooper 2016
Location in text
(pg/fig/table)
Multicenter, double-blind
Summary
1134
Fig 1
965
-Placebo
Summary
-1000 IU/d
Multivitamins taken containing up to 400 IU/day of
395
vitamin D for placebo and 1000 IU intervention
Caucasian
Table 1
United Kingdom.
Recruited at three study sites [University Hospital
394
Southampton NHS Foundation Trust, Southampton,
UK; Oxford University Hospitals NHS Trust, Oxford,
UK; Sheffield Hospitals NHS Trust (University of
Sheffield), Sheffield, UK]
Whole body BMC of the neonate;
Summary
Secondary outcomes included maternal 25(OH)D
concentration at 34 weeks’ gestation; change in
25(OH)D between 14 and 34 weeks’ gestation,
neonatal whole-body bone area and bone mineral
density, and neonatal bone indices at the spine
June, 2008 (14 weeks gestation (or as soon as possible
Summary
before 17 weeks’ gestation if recruited later) until
delivery)
November 2014
Summary
Placebo
1000 IU/d
Table 1
30.5 ±5.2
30.5 ±5.2
25.7
24.7
Low/high/unclear
Support for judgement
395
Low
Randomly assigned by a computer-generated sequence
in randomly permuted blocks of ten starting randomly
midway through the block, and sequentially
numbered, before delivery to the study sites, and then
dispensed in order by each study pharmacist
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Table C.6

(continued)

Pre/Post Data

Baseline data (ng/mL)

Placebo
Mean

SD

18.36

6.8

1000 IU
Number of
participants
569

Mean

SD

18.68

7.08

Placebo
Mean
Post data (ng/mL)
Overall Study
Evaluation outcome

SD

Number of
participants
565

1000 IU
Number of
participants
486

Mean

SD

Number of
participants
479

17.32
8.92
27.28
8.76
X Positive
Negative
Supplementation increased levels of serum 25(OH)D concentration to
reduce vitamin D repletion; supplementation (1000 IU/day) during
pregnancy on the primary outcome (offspring neonatal bone mineral
content) was not effective
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Table C.7

Data Extraction for Hashemipouri 2013

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention

Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Christine Rogers
Diane Tidwell
Effect of Vitamin D administration in vitamin-D deficient pregnant women
on maternal and neonatal serum calcium and vitamin D concentrations: a
randomized clinical trial
Hashemipouir 2013
Location in text
(pg/fig/table)
Open-label
16
130
Fig 1
109
-Control (multivitamin containing 400 IU and 200 mg Ca Abstract
daily) until delivery
16
-50,000 IU weekly plus multivitamin containing 400 IU
and 2000 mg Ca daily for 8 weeks
Iranian
Qazvin, Iran
Referred for prenatal care to an obstetric clinic
To determine whether treatment of low serum vitamin D
in pregnant women improves fetal growth indices
December 2011 (26 to 28 weeks pregnancy)
March 2012
Control
50,000 IU weekly
27.62 ±4.63
25.05 ±4.62
24.43 ±2.53
24.24 ±2.58
Low/high/unclear
Support for judgement
Unclear

Pre/Post Data

Baseline data (ng/mL)

Overall Study
Evaluation outcome

16

Mean

SD

17.5

4.8

50,000 IU
Number of
participants
54

Mean

SD

15.8

5.6

Control

Post data (ng/mL)

16
16
Table 1

Open-label, allocation was concealed and
randomization was performed using computergenerated random numbers; assignment into groups
was performed by an obstetrician
Control

Mean

16
16
Abstract

SD

Number of
participants
55

50,000 IU
Number of
participants
54

Mean

SD

Number of
participants
55

15.9
6.6
47.8
11.1
X Positive
Negative
Supplementation increased vitamin D and calcium levels significantly
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Table C.8

Data Extraction for Hollis 2011

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date
Age (years)
BMI (%)
Risk of Bias
Pre/Post Data

Baseline data (ng/mL)

Christine Rogers
Diane Tidwell
Vitamin D supplementation during pregnancy: Double-blind, randomized
clinical trial of safety and effectiveness
Hollis 2011
Location in text
(pg/fig/table)
Single-center, Double blinded
2342/Methods:
Study design
502
2345
350
Abstract/Fig 1
-400 IU group (Placebo)
Abstract
-2000 IU group
-4000 IU group
stratified by race; single pregnancy
2346
Season: April – September; October - March
Black, Hispanic, White
2346
South Carolina (latitude 32˚ N)
2352
Women that planned to receive ongoing prenatal care in
2342/Methods:
Charleston, SC area
Study participants
Safety and effectiveness of vitamin D supplementation
Abstract
2354
Jan 4, 2004; 12 - 16 weeks gestation until delivery
2342
July 31, 2009
2342
400 IU group
2000 IU group
4000 IU group 2346
27.0 ±5.6
27.4 ±5.7
26.6 ±5.4
≤30 78 (70.3)
87 (71.3)
89 (76.1)
>30 33 (29.7)
35 (28.7)
28 (23.9)
Low/high/unclear
Support for judgement 2343
Low
RCT, double blind; stratified blocked
randomization to balance by ethnicity
400 IU
(Placebo)

Evaluation outcome

4000 IU

Mean

SD

Number of
participants

Mean

SD

Number of
participants

Mean

SD

Number of
participants

24.64

10.84

164

23.32

8.92

166

23.28

8.72

167

Mean

Post data (ng/mL)
Overall Study

2000 IU

31.56

400 IU
(Placebo)

2000 IU

4000 IU

SD

Number of
participants

Mean

SD

Number of
participants

Mean

SD

14.6

111

39.32

13.68

122

44.4

16.16

Number of
participants

117

X Positive
Negative
Vitamin D supplementation with 4000 IU/d was most effective in achieving
vitamin D sufficiency throughout pregnancy in a diverse group of women
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Table C.9

Data Extraction for Karamali 2015

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date

Risk of Bias

Age (years)
BMI (kg/m2)

Christine Rogers
Diane Tidwell
Effect of High-Dose vitamin D supplementation on metabolic status and
pregnancy outcomes in pregnant women at risk for pre-eclampsia
Karamali 2015
Location in text
(pg/fig/table)
Double-blinded, stratified
60
Abstract, 869
60
-Placebo
Abstract
-50,000 IU every two weeks for 12 weeks
Multivitamin taken (400 IU vitamin D);
868
pregnant women at risk for pre-eclampsia
Abstract
Iranian
Arak, Iran
868
Women primigravida and at risk for pre-eclampsia
868(Subjects/
Methods)
To investigate effect of supplementation on metabolic 868(Introduction)
status and pregnancy outcomes
July, 2014 (20 to 32 weeks gestation)
868(Subjects/
Methods)
October, 2014
868(Subjects/
Methods)
27.4 ±5.2
869(Results)
25.9 ±4.6
Low/high/unclear
Support for judgement
868
Low

Pre/Post Data

Baseline data (ng/mL)

A trained midwife randomized allocation sequence
with a computer random number generator.
Placebo

Mean

SD

17.10

2.21

50000 IU
Number of
participants
30

Mean

SD

16.99

1.40

Placebo
Mean
Post data (ng/mL)
Overall Study
Evaluation outcome

SD

Number of
participants
30

50000 IU
Number of
participants
30

Mean

SD

Number of
participants
30

17.37
4.04
34.91
2.36
X Positive
Negative
Vitamin D supplementation had significantly increased serum 25(OH)D
concentrations; metabolic status improved in some outcomes
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Table C.10

Data Extraction for Karamali & Asemi 2016

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention

Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date

Risk of Bias

Age (years)
BMI (kg/m2)

Pre/Post Data

Baseline data (ng/mL)

Christine Rogers
Diane Tidwell
Calcium plus vitamin D supplementation affects pregnancy outcomes in
gestational diabetes: randomized, double-blind, placebo-controlled trial
Karamali & Asemi, 2016
Location in text
(pg/fig/table)
Double-blinded
60
Abstract
60
- two placebos of vitamin D (one at baseline and
157(Methods)/
another at day 21 of the intervention) and placebos of
Abstract
Ca every day (Ca + vitamin D)
-50,000 IU (one at baseline and another at day 21 of
the intervention) plus Ca (1000mg/d)
(6 weeks)
Women diagnosed with GDM
157 (Methods)
Iranian
Arak, Iran
157
Women attending maternity clinics screened for GDM
Methods
to assess the effects of Ca + vitamin D supplementation Abstract
on pregnancy outcomes in women with GDM
March 2014 (24-28 wks gestation)
157(Methods)
July 2014
157(Methods)
Placebo
50000 IU + Ca
159/Table 1
31.6 ±6.3
28.7 ±6.1
30.5 ±4.5
29.4 ±4.7
Low/high/unclear
Support for judgement
Methods
Low
Computer-generated random number; trained
midwife did the randomized allocation sequence,
enrolled participants and assigned participants to
interventions
Placebo
Mean

SD

20.8

14.4

50000 IU + Ca
Number of
participants
30

Mean

SD

17.3

10.9

Placebo

Post data (ng/mL)
Overall Study
Evaluation outcome

Mean

SD

21.3

14.4

Number of
participants
30

50000 IU + Ca
Number of
participants
30

Mean

SD

36.3

21.3

Number of
participants
30

X Positive
Negative
Vitamin D supplementation had significantly increased serum 25(OH)D
concentrations; metabolic status improved pregnant women with GDM led
to decreased caesarean section rate and hospitalization in newborns.
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Table C.11

Data Extraction for Mir 2016

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Study Notes
Population description
Location
Method of recruitment

Aim of study
Start date
End date

Risk of Bias

Age (years)
BMI (kg/m2)

Pre/Post data

Christine Rogers
Diane Tidwell
Efficacy and safety of vitamin D supplementation during pregnancy: A
randomized trial of two different levels of dosing on maternal and neonatal
vitamin D outcome
Mir 2016
Location in text
(pg/fig/table)
Open-label, parallel, prospective
Abstract
100
Abstract
87
Group 1 - 1000 IU/day; Group 2 - 30,000 IU month;
Abstract
Group 3 - 2000 IU/day; Group 4 - 60,000 IU/month
Recruitment done in summer months of May - July
Results
Kashmiri, India
Recruited from the out-patient department (OPD) of
Obstetrics and Gynaecology, SKIMS, during summer
of 2013, and some subjects from maternity hospital
(Lal Ded, Srinagar)
To study the safety and effectiveness of Vitamin D
supplementation during pregnancy
16 weeks gestation
Delivery
Group 1
Group 2
Group 3
Group 4
28.0 ±6.4 24.5 ±7.0
26.3 ±9.3
27.3 ±5.6
22.6 ±4.0 24.6 ±6.1
21.9 ±3.2
24.8 ±8.3
Low/high/unclear
Support for judgement
Unclear
Open-label, random
assignment
Group 1
1000 IU

Mean

Baseline data (ng/mL)

26.5

Mean

Baseline data (ng/mL)

26.0

Mean

Post data (ng/mL)

37.7

SD
16.0

Group 3
2000 IU
SD

17.1

Group 1
1000 IU
SD

11.3

Discussion
Materials/Methods

Introduction
Materials/Methods
Materials/Methods
Table 1

Group 2
30,000 IU

Number of
participants
26

Mean

SD

22.6

13.0

Number of
participants
27

Mean

SD

21.3

13.8

Number of
Participants
21

Mean

SD

36.1

9.9

100

Group 4
60,000 IU

Group 2
30,000 IU

Number of
participants
21

Number of
participants
26

Number of
participants
18

Table C.11

(continued)

Mean

Post data (ng/mL)
Overall Study
Evaluation outcome

41.2

Group 3
2000 IU
SD

12.6

Number of
participants
25

Group 4
60,000 IU

Mean

SD

44.7

13.1

Number of
participants
23

X Positive
Negative
2000 IU daily or 60,000 IU monthly supplementation of vitamin D is
effective and safe to achieve an acceptable serum vitamin D 25(OH) level
throughout pregnancy
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Table C.12

Data Extraction for Mojibian 2015

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Study Notes

Population description
Location
Method of recruitment
Aim of study

Start date
End date

Risk of Bias

Age (years)
BMI (kg/m2)

Christine Rogers
Diane Tidwell
The effect of vitamin D supplementation on maternal and neonatal
outcome: A randomized clinical trial
Mojibian 2015
Location in text
(pg/fig/table)
Not blinded to pregnant women and researchers
Materials/Methods
500
Fig 2
389
Group A (400 IU/day)
Abstract
Group B (50,000 IU every two weeks)
Incidence of gestational diabetes (GDM),
Abstract
gestational hypertension, preeclampsia and preterm
labor, vitamin D status at term and neonatal
outcomes 12 weeks gestation to delivery
Iranian
Yazd, Iran
Materials/Methods
Recruited from two prenatal clinics in Yazd, Iran
Materials/Methods
To assess the effects of vitamin D supplementation
Abstract
on gestational diabetes, gestational hypertension,
preeclampsia and preterm labor, serum level of 25
(OH) D at the time of delivery
2010 (12-16 weeks gestation until delivery)
Materials/Methods;
Abstract
2012
Materials/Methods
Group A
Group B
Table 1
27.3 ±4.9
27.8 ±5.0
26.8 ±4.0
25.9 ±4.8
Low/high/unclear
Support for judgement
Materials/Methods
High

Pre/Post Data

Baseline data (ng/mL)

Computer generated random number list; pregnant
women and researchers were not blinded to treatment
assignment
Group A
400 IU

Mean

SD

15.31

5.19

Number of
participants
250

Group B
50,000 IU
Mean

SD

14.46

5.19

Group A
400 IU
Mean
Post data (ng/mL)
Overall Study
Evaluation outcome

SD

27.2
18.8
X Positive
Negative

Number of
participants
203

Number of
participants
250

Group B
50,000 IU
Mean

SD

37.9

19.8

Number of
participants
186

Vitamin D levels significantly higher at delivery; supplementation
decreased incidence of GDM
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Table C.13

Data Extraction for Roth 2013

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Study Notes
Population description
Location
Method of recruitment

Aim of Study
Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Christine Rogers
Diane Tidwell
Randomized placebo-controlled trial of high-dose prenatal third-trimester
vitamin D3 supplementation in Bangladesh: The AViDD trial
Roth 2013
Location in text
(pg/fig/table)
Double-blinded
Abstract
160
Abstract
130
Fig 1
-placebo
Abstract
-35000 IU/week
(10 weeks)
Healthy pregnant women
Results
Dhaka, Bangladesh (23°N)
Recruited from Shimantik Urban Primary Health Care
Project maternity center, a non-governmental, nonprofit facility that provides basic antenatal and
obstetric services
To evaluate the effect of high-dose prenatal vitamin
D3 supplementation on maternal and neonatal serum
25(OH) concentration
August 2010 to January 2011 (26 to 29 weeks
gestation)
September 2010 to April 2011
Overall
Placebo
35,000 IU
22.4 ±3.5
22.4 ±3.4
22.4 ±3.5
23.0 ±3.3
22.8 ±3.5
22.1 ±3.1
Low/high/unclear
Low

Pre/Post Data

Baseline data (ng/mL)

SD

17.6

8.36

Post data (ng/mL)
Overall Study
Evaluation outcome

SD

Subjects/Methods
Subjects/Methods
Table 1

35,000 IU
Number of
participants
80

Mean

SD

18.16

7.36

Placebo
Mean

Abstract

Support for judgement
Abstract
All participants, study personnel and study
investigators were blinded to treatment allocation.

Placebo
Mean

Abstract
Subjects/Methods

Number of
participants
80

35,000 IU
Number of
participants
63

Mean

SD

Number of
participants
67

15.36
7.24
53.76
12.28
X Positive
Negative
Serum vitamin D 25(OH) levels raised above the IOM cut-off for
sufficiency
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Table C.14

Data Extraction for Sabet 2012

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date
Age (years)
BMI (kg/m2)
Weight (kg)
Risk of Bias

Christine Rogers
Diane Tidwell
Vitamin D supplementation in pregnant Iranian women: Effects on maternal
and neonatal vitamin D and parathyroid hormone status
Sabet 2012
Location in text
(pg/fig/table)
Double-blinded
Abstract
50
60
50
-Placebo
61
-100,000 IU monthly (3 times)
27-28 weeks gestation to delivery
60
Iranian
59
Tehran, Iran (35 °N)
Subjects/methods
60
Women scheduled to deliver at Mahdieh Hospital
Subjects/methods
60
To determine 25(OH)D and iPTH status in pregnancy
Abstract
and evaluate effects of monthly 100,000 IU
59
supplemental dose
2009
Subjects/methods
60
2010
Subjects/methods
60
Placebo
100,000 IU
26.0 ± 6.2
26.6 ± 4.7
62; Table 1
70.0 ± 9.0
Low/high/unclear

72.0 ± 10.0
Support for judgement

Subjects/methods;
61
Randomly allocated to treatment

Low
Pre/Post Data

Baseline data (ng/mL)

Placebo

100,000 IU

Mean

SD

Number of
participants

Mean

SD

Number of
participants

38.3

23.2

25

33.5

21.4

25

Placebo

Post data (ng/mL)
Overall Study
Evaluation outcome

Mean

SD

29.4

16

100,000 IU
Number of
participants
25

Mean

SD

61.45

30

Number of
participants
25

X Positive
Negative
Vitamin D supplementation of 100,000 IU/month is safe for pregnant women
with a significant increase
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Table C.15

Data Extraction for Samimi 2016

Data extracted by:
Data checked by:
Article
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention

Study Notes

Population description
Location
Method of recruitment
Outcome measures
Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Christine Rogers-Kelly
Diane Tidwell
The effects of vitamin D plus calcium supplementation on metabolic profiles,
biomarkers of inflammation, oxidative stress and pregnancy outcomes in
pregnant women at risk for pre-eclampsia
Samimi, 2016
Location in text
(pg/fig/table)
Prospective randomized
Abstract
60
Abstract
60
-placebo
Abstract
-50000 IU vitamin D3 every 2 weeks plus 1000 mg/day
calcium supplements
(12 weeks)
Women at-risk for pre-eclampia
507
A multivitamin mineral capsule (containing 400 IU
vitamin D and 500 mg calcium) taken from the second half
of pregnancy.
Iranian
Kashan, Iran
506
Women at-risk for pre-eclampia
506
After 12 weeks mean (SD) serum 24(OH)D concentrations 508
had significantly increased in the vitamin D plus calcium
group
September 2014
506
February 2015
506
Placebo
50,000 IU
509
27.1 ±5.2
27.3 ±3.7
25.6 ±4.0
27.4 ±3.3
Low/high/unclear
Support for judgement
507
Low

The randomized allocation sequence from a
computer random number generator was obtained by
a trained midwife at the maternity clinic.
Randomization and allocation were concealed from
both researchers and pregnant women until the
statistical analysis was completed.

Pre/Post Data
Baseline data (ng/mL)

Placebo
Mean

SD

16.2

3.5

50000 IU
Number of
participants
30

Mean

SD

13.1

6.4

Placebo

Post data (ng/mL)

Mean

SD

16.3

4.9

Number of
participants
40

50000 IU
Number of
participants
30

105

Mean
21.3

SD
8.4

Number of
participants
30

Table C.15

(continued)

Overall Study
Evaluation outcome

X Positive
Negative
Vitamin D supplementation plus calcium significantly increased serum
25(OH)D concentrations; vitamin D supplementation has beneficial effects on
glycemic status, HDL-cholesterol, SH and blood pressure for at risk GDM
women
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Table C.16

Data Extraction for Soheilykhan 2013

Data extracted by:
Data checked by:
Article
Author(s)
Study Characteristics
RCT design/notes
Participants
-total completed
Intervention
Notes
Population description
Location
Method of recruitment
Outcome measures
Start date
End date

Age (years)
BMI (kg/m2)
Risk of Bias

Christine Rogers-Kelly
Dr. Diane Tidwell
The effect of different doses of vitamin D supplementation on insulin
resistance during pregnancy
Soheilykhan 2013
Location in text
(pg/fig/table)
Not blinded
2/1
120
1/methods
-200 IU/d
-50000 IU/month (2000 IU/d)
-50000 IU/week (4000 IU/d)
From 12 weeks of pregnancy until delivery
Iranians
Yazd, Iran
From two prenatal clinics
50000 IU vitamin D every two weeks form the 12 weeks of
pregnancy until delivery for pregnant women with vitamin
D deficiency recommended
2009
2011
26.0 ±4.5
25.7 ±4.3
Low/high/unclear
Support for judgement
High

Pre/Post Data

Baseline data (ng/mL)

Evaluation outcome

2

2

Computer generated random number lists;
pregnant women and researchers were not
blinded to treatment
Group A
200 IU

Group B
2000 IU

Group C
4000 IU

Mean

SD

Number of
participants

Mean

SD

Number of
participants

Mean

SD

Number of
participants

8.3

7.8

40

7.3

5.3

40

7.3

5.9

40

Mean

Post data (ng/mL)
Overall Study

1

17.7

Group A
200 IU
SD

No.
participants

Mean

9.3

35

27.2

Group B
2000 IU
SD

No.
participants

Mean

10.7

38

34.1

Group C
4000 IU
SD

No.
participants

11.5

40

X Positive
Negative
Vitamin D supplementation increased significantly; supplementation of
pregnant women with 50 000 IU vitamin D every 2 weeks improved insulin
resistance significantly
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Table C.17

Data Extraction for Vaziri 2016

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
- total completed
Intervention
Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Christine Rogers
Diane Tidwell
A randomized controlled trial of vitamin D supplementation on perinatal
depression: in Iranian pregnant mothers
Vaziri 2016
Location in text
(pg/fig/table)
Single-blind
Methods:sample
size
153
Fig 1
130
-Control (two placebo pills)
Methods:design
-2000IU/day
Both control and treatment took multivitamin
Methods:design
supplementations contained 200–400 IU of vitamin D
Season – autumn, winter, spring
Nulliparous/multiparous pregnant Iranian women
Methods:
Shiraz, Iran
Methods:setting
Women invited under prenatal care in a teaching
Abstract/methods
hospital
To evaluate the effect of vitamin D3 supplementation
Abstract
on prenatal depression scores
November 2014 (26-28 weeks gestation)
Methods:setting
October 2015
Methods:setting
Control/Placebo
2000 IU/day
Table 1
26.22 ±4.33
26.40 ±4.88
Low/high/unclear

Support for judgement

Methods/sample
size
Stratified random sampling using block
randomization strategy

Low
Pre/Post Data

Baseline data (ng/mL)

Control/Placebo
Mean

SD

11.89

6.40

Number of
participants
78

Evaluation outcome

Mean

SD

12.84

7.91

Number of
participants
75

Control/Placebo
2000 IU
SD
Number of
Mean
SD
Number of
participants
participants
12.07
5.98
74
17.46
10.09
74
X Positive
Negative
Vitamin D levels increased; consuming 2000 IU vitamin D3 daily during late
pregnancy was effective in decreasing perinatal depression levels
Mean

Post data (ng/mL)
Overall Study

2000 IU
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Table C.18

Data Extraction for Wagner 2013

Data extracted by:
Data checked by:
Reference
Author(s)
Study
Characteristics
RCT design/notes
Participants
-Total completed
Intervention
Notes
Population
description
Location
Method of
recruitment
Study Notes

Aim of study
Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Pre/Post Data
Baseline data(ng/mL)

Christine Rogers
Diane Tidwell
Health characteristics and outcomes of two randomized
vitamin D supplementation trials during pregnancy: A
combined analysis
Wagner 2013
Two-center, Double-blinded
758
341
Control (400 IU/d)
2000 IU/d
4000 IU/d
Stratified by race
African American, Caucasian, Hispanic
Columbia, South Carolina; North Charleston, SC
Unclear

3

Spring (April -May), Summer (June-September), Fall
(October-November) and Winter (December -March)
Conducted at two centers; two different start and finish
dates
To determine if 4000 IU/d is safe during pregnancy
January 2004 (NICHD Trial) (12-16 weeks gestation)
August 2010 (NICHD Trial)
Control (400 IU/d)
2000IU/d
4000IU/d
25.0 ±5.1
24.5 ±5.3
25.4 ±5.0

7

Low/high/unclear

Support for judgement

4

Low

Computer generated, and assignments blinded to all
participants and investigators except for study
biostatistician

400 IU (Control)
Mean

SD

24.6

10.9

No.
participants

166

2000 IU
Mean

SD

23.2

8.6

400 IU (Control)
Post data (ng/mL)
Overall Study
Evaluation outcome

Location in text
(pg/fig/table)
3:methods
Fig 2

3
Abstract
3
3
Table 1

4000 IU

No.
participants

167

Mean

SD

22.8

9.7

2000 IU

No.
participants

168

4000 IU

Mean

SD

No.
participants

Mean

SD

No.
participants

Mean

SD

No.
participants

30.7

14.1

110

37.1

14.7

117

41.9

16.2

114

X Positive
Negative
Vitamin D supplementation improved maternal and neonatal status
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Table C.19

Data Extraction for Yap 2014

Data extracted by:
Data checked by:
Reference
Author(s)
Study Characteristics
RCT design/notes
Participants
-Total completed
Intervention
Study Notes
Population description
Location
Method of recruitment
Aim of study
Start date
End date
Age (years)
BMI (kg/m2)
Risk of Bias

Pre/Post Data
Baseline data (ng/mL)

Post data (ng/mL)
Overall Study
Evaluation outcome

Christine Rogers
Diane Tidwell
Vitamin D supplementation and the effects on glucose metabolism during
pregnancy: A randomized controlled trial
Yap 2014
Location in text
(pg/fig/table)
Double blinded
209
4/fig 1
179
400 IU/d
5000 IU/d
women with GDM
Multi-cultural
Table 1
Sidney, Australia
2/Design,
Methods
Women with GDM
Objective
February 2010 (14 wks gestation)
November 2011 (26-28 wks gestation)
28.8 ±4.9
29.5 ±4.7
3/table 1
26.1 ±5.8
25.4 ±5.2
Low/high/unclear
Support for judgement
Unclear
Randomization is unclear, some participants
were assigned to a nonrandomized low dose
group
400 IU
Mean

SD

18.0

7.0

Mean

400 IU
SD

24.0

9.0

5000 IU
Number of
participants
90

Mean

SD

20.0

7.0

Number of
participants
90

Mean
36.0

Number of
participants
89

5000 IU
SD
Number of
participants
11.0
89

__X__Positive
_____Negative
Vitamin D supplementation at 5000 IU/d is safe supplementation for blood
glucose levels not effective

110

APPENDIX D
STUDIES EXCLUDED FROM THE META-ANALYSIS
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Table D.1

Studies Excluded from the Meta-Analysis

Study (first
author) Year
Asemi 2012

Reason for Exclusion

Co-morbidities

Serum vitamin D not
measured

Effect on metabolic
profile at risk for preeclampsia

Brooke 1980

Effect on calcium status
and fetal growth

Cockburn 1980

Baseline SD for
control and
intervention not
reported
SD data not reported

Dawodu 2013

Post SD not reported

Delvin 1986

SD data not
reported; standard
error mean (SEM)
reported

Effect on pregnancy and
neonatal calcium levels

Dimetris 2016

Sub study of Roth
2013

To evaluate the effect of
high-dose prenatal
vitamin D3
supplementation on
maternal and neonatal
serum 25(OH)D
concentration

Etemadifar 2015

Post vitamin D
levels reported 6
months after
delivery

Women with multiple
sclerosis (MS)

Effect of vitamin D
supplementation during
pregnancy and outcome
of newborn
effectiveness and safety
of prenatal 2000 IU and
4000 IU/d compared
with 400 IU/d vD3
supplementation

112

Outcomes
Increased levels of
serum vitamin D
25(OH)D
concentration
beneficial on
metabolic indices
Vitamin D
supplementation
beneficial to both
mother and infants
Vitamin D
supplementation
beneficial to mother
Vitamin D
supplementation of
2000 and 4000 IU/d
appears safe in
pregnancy with 4000
IU/d most effective in
optimizing serum
25(OH)
concentrations
Increased serum
Vitamin D levels
improved effects on
neonatal calcium
homeostasis

Increased serum
25(OH)D
concentration
remained elevated
following doses of
35,000 IU in
pregnant women

High dose vitamin D3
supplementation had
significant effect on
serum 25(OH)D levels

Table D.1

(continued)

Goldring 2013

SD not reported

Childhood wheezing in
offspring

Grant, 2014

SD data not
reported; data
reported as median

Effect on maternal and
infants vitamin D status

Harrington 2014

Repeat of Roth 2013
study

Maternal-fetal of
antenatal
supplementation on
fetal-neonatal calcium
homeostasis

Hashemipour
2013

Study presented data
that appeared to be
an outlier

None

Vitamin D levels
improved maternal
status

Hossain, 2014

SD data not
reported; data
reported as median,

effect on neonatal
anthropometry

HosseinzadehShamir-Anar 2012

SD data not
reported; data
reported as median

Effects of
supplementation on
GDM

Kalra, 2012

SD data not
reported; data
reported as median

effect on infant
anthropometry

Maternal vitamin D
supplementation
improved maternal
and neonatal vitamin
D status
A single dose of
300,000 IU is
effective and safe to
improve vitamin D
status in GDM
Large dose improved
maternal serum
25(OH)D
concentrations

113

Supplementation
improved vitamin D
status among pregnant
women.
Prenatal vitamin D
supplementation in
late pregnancy was
not associated with
decreased wheezing in
offspring
Maternal serum
25(OH) concentration
increased from
enrollment to 36
weeks gestation in
1000 IU and 2000 IU
groups sustaining this
increase for longer
duration
High dose antenatal
third-semester vitamin
D supplementation
increased calcium
levels in neonate

Table D.1

(continued)

Mallet 1986

No post data
reported

Effect on birth weight at
delivery

March 2015

SD data not
reported; 95% CI
reported

Effect of
supplementation in
gestation until
postpartum

Marya 1981

Baseline data not
Vitamin D
reported; data
supplementation in
reported as Heat
pregnancy
Labile alkaline
phosphatase (HLAP)

MohammadAlizadenCharandabi 2015

No serum Vitamin D
25(OH)D
concentrations
reported

Effect of Vitamin D and
calcium during
pregnancy and birth
outcomes

Moon, 2016

SD data not
available

Effect of Vitamin D
supplementation in
maternal outcomes and
environmental
characteristics

Rodda 2015

SD data not
reported; 95% CI
reported

Prevention of Vitamin D
deficiency in newborn

114

A single dose of
200,000 IU (5 mg)
given in the seventh
month increased
serum vitamin D
concentration
Vitamin D dose of 50
mg effective at 8
weeks postpartum;
increase levels of
serum concentration
during pregnancy
1,200 IU/d in third
trimester showed
improvement,
however, Vitamin D
in two large doses of
600,000 IU was more
beneficial
There was no effect
on duration of
pregnancy, type of
delivery and
gestational age
Vitamin D
supplementation in
late pregnancy
achieved higher serum
Vitamin D 25(OH)
concentrations for
women that gained
less weight during
pregnancy, delivered
in the summer and had
higher concentration
in early pregnancy
Vitamin D
supplementation
increased maternal
serum 25(OH)D
concentration at
delivery and prevents
neonatal vitamin D
deficiency

Table D.1

(continued)

Roth, Mahmud,
Raqib, Akhtar,
Black, Baqui 2013

SD data not
reported; 95% CI
reported

Effect of high dose
supplementation in third
trimester

Vitamin D dose of
70,000 IU and 35,000
IU in third trimester
effective and nonhypercalcemic

Roth, Mahmud,
Raqib,Akhtar,
Perumal, Pezzack,
Baqui 2013
Sablok 2015

Meta-analysis data
was out of range in
CI

None

Vitamin D levels
raised above
50nmol/L

Mean and standard
deviation not report
in baseline
No mean or SD data
given

Vitamin D
supplementation and
neonatal outcomes
Effect of
supplementation on
gestational diabetes in
high risk

Effect of vitamin D
supplementation

Shakiba 2013

No mean or SD data
given

Effect to prevent
deficiency in neonates

Taghizadeh 2014

Vitamin D status not
reported

None

Wall 2016

No pre-data; post
data reported a
median

effect of vitamin D
supplementation during
pregnancy on breastmilk vitamin D activity
(VDA)

Vitamin D dose >
50,000 IU/month
required during
second and third
trimester to achieve
levels beneficial for
neonate
significant increase in
maternal serum
calcium and
magnesium levels
higher amount of
vitamin D3
supplementation
(2000 IU/d) compared
with the lower amount
of vitamin D3
supplementation
(1000 IU/d) resulted
in higher serum
concentrations and
also in the amount of
breast-milk VDA

Shahgheibi 2016
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Vitamin D
supplementation for
high-risk pregnant
women in the first and
second trimesters has
an effective impact on
gestational diabetes
with increased levels
of vitamin D

Table D.1

(continued)

Yazdchi 2016

SD data not
reported; median
data reported

Yu 2009

SD data not reported

Effects of
supplementation on
metabolic indices, hsCRP levels in GDM
Effects of daily and
single-dose
supplementation in
pregnant women and
babies at delivery

50,000 IU dosed to
GDM patients for two
months improved
vitamin D status
Single or daily dose of
supplementation
improved serum
Vitamin D
concentrations

Abbreviations: 25(OH)D: 25-hydroxyvitamin D, CI: confidence interval, SD: standard
deviation
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APPENDIX E
META-ANALYSIS DATA ENTRY AND CALCULATIONS
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Table E.1
First author
and publication
year

Asemi, Hashemi
2013
Asemi, Samimi
2014
Asemi 2013
Asemi 2015
Cooper 2016
Dimitris 2016
Hashemipour
2013
Hollis 2011

Meta-Analysis Data Entry and Calculations
CMA format

Standardized
By

Effect
direction

Mean, SD in
each group
Mean, SD in
each group
Mean, SD in
each group
Mean, SD in
each group
Mean, SD in
each group
Mean, SD in
each group
Mean, SD in
each group

Post score,
SD
Post score,
SD
Post score,
SD
Post score,
SD
Post score,
SD
Post score,
SD
Post score,
SD

Positive

None

Positive

None

Positive

None

Positive

None

Positive

None

Positive

None

Positive

None

Mean, SD in
each group

Post score,
SD

Positive

Equations for pooling multiple interventions

Calculation

Conversion calculation
1 ng/mL = 2.5 nmol/L
Baseline:
Mean (M)
Standard Deviation (SD)

61.6 nmol/L = 24.64 ng/mL 27.1 nmol/L = 10.84 ng/mL
58.3 nmol/L = 23.32 ng/mL 22.3 nmol/L = 8.92 ng/mL
58.2 nmol/L = 23.28 ng/mL 21.8 nmol/L = 8.72 ng/mL

Post:
(SD)

Karamali 2015
Karamali 2016

Mean, SD in
each group
Mean, SD in
each group

Post score,
SD
Post score,
SD

Positive
Positive
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Mean (M)

Standard Deviation

78.9 nmol/L = 31.56 ng/mL 36.5 nmol/L = 14.6 ng/mL
98.3 nmol/L = 39.32 ng/mL 34.2 nmol/L = 13.68 ng/mL
111.0 nmol/L = 44.4 ng/mL 40.4 nmol/L = 16.16 ng/mL

None
None

Table E.1
Mir 2016

(continued)
Mean, SD in
each group

Post score,
SD

Positive

Equations for pooling multiple interventions

Pre mean
Group ‘1 + 2’ combined – 21.871
Group ‘1 + 2’ and group 3 – 24.115
Pre standard deviation
Group ‘1 + 2’ combined – 13.304
Group ‘1 + 2’ and group 3 – 15.325
Post mean
Group ‘1 + 2’ combined – 40.88
Group ‘1 + 2’ and group 3 – 41.054
Post standard deviation (SD)
Group ‘1 + 2’ combined – 12.463
Group ‘1 + 2’ and group 3 – 12.384
Mojibian 2015
Roth 2013

Mean, SD in
each group
Mean, SD in
each group

Post score,
SD
Post score,
SD

Positive

None

Positive

1 ng/L = 2.5 nmol/L
Baseline mean:
SD:
44.0 nmol/L = 17.6 ng/mL
20.9 nmol/L = 8.36
ng/mL
45.4 nmol/L = 18.16 ng/mL 18.4 nmol/L = 7.36
ng/mL
Post mean:
SD:
38.4 nmol/L = 15.36 ng/mL 18.1 nmol/L = 7.24
ng/mL
134.4 nmol/L = 53.76 ng/mL 30.7 nmol/L = 12.28
ng/mL

Sabet, 2012

Mean, SD in
each group

Post score,
SD

Positive
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None

Table E.1
Samimi 2016
Soheilykhah
2012

Vaziri 2016
Wagner 2013

Yap 2014

(continued)
Mean, SD in
each group
Mean, SD in
each group

Post score,
SD
Post score,
SD

Positive

None

Positive

Equations for pooling multiple interventions

Mean, SD in
each group
Mean, SD in
each group

Post score,
SD
Post score,
SD

Positive

None

Positive

Equations for pooling multiple interventions

Mean, SD in
each group

Post score,
SD

Positive

None
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